Methods and systems for modifying bioactive agent use

ABSTRACT

Methods, computer program products, and systems are described that include measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual and/or modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is related to and claims the benefit of theearliest available effective filing date(s) from the following listedapplication(s) (the “Related Applications”) (e.g., claims earliestavailable priority dates for other than provisional patent applicationsor claims benefits under 35 USC §119(e) for provisional patentapplications, for any and all parent, grandparent, great-grandparent,etc. applications of the Related Application(s)).

RELATED APPLICATIONS

-   -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION TREATMENT        SELECTION METHODS AND SYSTEMS, naming Roderick A. Hyde;        Muriel Y. Ishikawa; Eric C. Leuthardt; Royce A. Levien;        Robert W. Lord; Mark A. Malamud; Elizabeth A. Sweeney; Lowell L.        Wood, Jr.; and Victoria Y. H. Wood as inventors, filed Apr. 24,        2008, application Ser. No. 12/150,122, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION TREATMENT        MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed May 13,        2008, application Ser. No. 12/152,266, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION TREATMENT        ALTERATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed May 21,        2008, application Ser. No. 12/154,275, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION THERAPEUTIC        PRODUCTS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y.        ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD;        MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND        VICTORIA Y. H. WOOD as inventors, filed May 30, 2008,        application Ser. No. 12/156,440, which is currently co-pending,        or is an application of which a currently co-pending application        is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled SIDE EFFECT AMELIORATING        COMBINATION THERAPEUTIC PRODUCTS AND SYSTEMS, naming RODERICK A.        HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 5,        2008, application Ser. No. 12/156,949, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION TREATMENT        MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 6,        2008, application Ser. No. 12/157,160, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION TREATMENT        SELECTION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 13,        2008, application Ser. No. 12/157,922, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION TREATMENT        MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 13,        2008, application Ser. No. 12/157,989, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled COMBINATION TREATMENT        ALTERATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 19,        2008, application Ser. No. 12/214,547, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 3,        2008, application Ser. No. 12/217,509, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 7,        2008, application Ser. No. 12/217,620, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 15,        2008, application Ser. No. 12/218,503, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 16,        2008, application Ser. No. 12/218,627, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States patent application entitled SYSTEMS AND APPARATUS FOR        MEASURING A BIOACTIVE AGENT EFFECT, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 25,        2008, application Ser. No. 12/220,706, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Aug. 22,        2008, application Ser. No. 12/229,531, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.

The United States Patent Office (USPTO) has published a notice to theeffect that the USPTO's computer programs require that patent applicantsreference both a serial number and indicate whether an application is acontinuation or continuation-in-part. Stephen G. Kunin, Benefit ofPrior-Filed Application, USPTO Official Gazette Mar. 18, 2003, availableat http://www.uspto.gov/web/offices/com/sol/og/2003/week11/patbene.htm.The present Applicant Entity (hereinafter “Applicant”) has providedabove a specific reference to the application(s) from which priority isbeing claimed as recited by statute. Applicant understands that thestatute is unambiguous in its specific reference language and does notrequire either a serial number or any characterization, such as“continuation” or “continuation-in-part,” for claiming priority to U.S.patent applications. Notwithstanding the foregoing, Applicantunderstands that the USPTO's computer programs have certain data entryrequirements, and hence Applicant is designating the present applicationas a continuation-in-part of its parent applications as set forth above,but expressly points out that such designations are not to be construedin any way as any type of commentary and/or admission as to whether ornot the present application contains any new matter in addition to thematter of its parent application(s).

All subject matter of the Related applications and of any and allparent, grandparent, great-grandparent, etc. applications of the Relatedapplications is incorporated herein by reference to the extent suchsubject matter is not inconsistent herewith.

TECHNICAL FIELD

This description relates to methods and systems for combining medicinewith an artificial sensory experience.

SUMMARY

In one aspect, a method includes but is not limited to measuring atleast one effect of a combined bioactive agent and artificial sensoryexperience on an individual and modifying at least one of the bioactiveagent or the artificial sensory experience at least partially based onthe at least one effect. In addition to the foregoing, other methodaspects are described in the claims, drawings, and text forming a partof the present disclosure.

In one or more various aspects, related systems include but are notlimited to circuitry and/or programming for effecting theherein-referenced method aspects; the circuitry and/or programming canbe virtually any combination of hardware, software, and/or firmwareconfigured to effect the herein-referenced method aspects depending uponthe design choices of the system designer.

In one aspect, a system includes but is not limited to means formeasuring at least one effect of a combined bioactive agent andartificial sensory experience on an individual and means for modifyingat least one of the bioactive agent or the artificial sensory experienceat least partially based on the at least one effect. In addition to theforegoing, other method aspects are described in the claims, drawings,and text forming a part of the present disclosure.

In one aspect, a system includes but is not limited to circuitry formeasuring at least one effect of a combined bioactive agent andartificial sensory experience on an individual and circuitry formodifying at least one of the bioactive agent or the artificial sensoryexperience at least partially based on the at least one effect. Inaddition to the foregoing, other method aspects are described in theclaims, drawings, and text forming a part of the present disclosure.

In one aspect, a computer program product includes but is not limited toa signal-bearing medium bearing one or more instructions for measuringat least one effect of a combined bioactive agent and artificial sensoryexperience on an individual and one or more instructions for modifyingat least one of the bioactive agent or the artificial sensory experienceat least partially based on the at least one effect. In addition to theforegoing, other method aspects are described in the claims, drawings,and text forming a part of the present disclosure.

In one aspect, a system includes but is not limited to a computingdevice and instructions that when executed on the computing device causethe computing device to measure at least one effect of a combinedbioactive agent and artificial sensory experience on an individual andmodify at least one of the bioactive agent or the artificial sensoryexperience at least partially based on the at least one effect. Inaddition to the foregoing, other method aspects are described in theclaims, drawings, and text forming a part of the present disclosure.

The foregoing is a summary and thus may contain simplifications,generalizations, inclusions, and/or omissions of detail; consequently,those skilled in the art will appreciate that the summary isillustrative only and is NOT intended to be in any way limiting. Otheraspects, features, and advantages of the devices and/or processes and/orother subject matter described herein will become apparent in theteachings set forth herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 2 illustrates an operational flow representing example operationsrelated to selecting a combination of at least one prescriptionmedication and at least one artificial sensory experience.

FIG. 3 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 4 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 5 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 6 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 7 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 8 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 9 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 10 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 11 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 12 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 13 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 14 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 15 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 16 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 17 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 18 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 19 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 20 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 21 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 22 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 23 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 24 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 25 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 26 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 27 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 28 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 29 illustrates an operational flow representing example operationsrelated to selecting a combination of at Least one prescriptionmedication and at least one artificial sensory experience.

FIG. 30 illustrates a computer program product related to selecting acombination of at least one prescription medication and at least oneartificial sensory experience.

FIG. 31 illustrates a system related to selecting a combination of atleast one prescription medication and at least one artificial sensoryexperience.

FIG. 32 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 33 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 34 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 35 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 36 illustrates an operational flow representing example operationsrelated to modifying at least one artificial sensory experience.

FIG. 37 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 38 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 39 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 40 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 41 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 42 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 43 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 44 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 45 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 46 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 47 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 48 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 49 illustrates a computer program product related to modifying acombination of at least one prescription medication and at least oneartificial sensory experience.

FIG. 50 illustrates a system related to modifying a combination of atleast one prescription medication and at least one artificial sensoryexperience.

DETAILED DESCRIPTION

In the following detailed description, reference is made to theaccompanying drawings, which form a part hereof. In the drawings,similar symbols typically identify similar components, unless contextdictates otherwise. The illustrative embodiments described in thedetailed description, drawings, and claims are not meant to be limiting.Other embodiments may be utilized, and other changes may be made,without departing from the spirit or scope of the subject matterpresented here.

FIG. 1 illustrates a system 100 for accepting at least one attribute ofat least one individual, querying at least one database at least partlybased on the at least one attribute, selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual, and presenting an indication of the at leastone prescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. The system 100 may include acceptor module 102,querier module 104, selector module 106, presenter module 108,implementer module 138, and/or modifier module 140. Acceptor module 102may receive attribute 120 from network storage 110, memory device 112,database entry 114, and/or user interface 116. User interface 116 mayreceive information from user 118. User 118 may include health careprovider 136. Querier module 104 may search database 122. Database 122may include medication database 124 and/or artificial sensory experiencedatabase 126. Presenter module 108 may present to health care provider128, output device 130, and/or individual 134. Output device 130 mayinclude mobile device 132. Modifier module 140 may include restrictormodule 142, granter module 144, alterer module 146, adder module 148,deleter module 150, and/or acceptor module 152. System 100 generallyrepresents instrumentality for accepting at least one attribute of atleast one individual, querying at least one database at least partlybased on the at least one attribute, selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual, and presenting an indication of the at leastone prescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. The operations of accepting at least oneattribute of at least one individual, querying at least one database atleast partly based on the at least one attribute, selecting from the atleast one database at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual, and presenting an indication of the at leastone prescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual may be accomplished electronically, such as witha set of interconnected electrical components, an integrated circuit,and/or a computer processor.

FIG. 2 illustrates an operational flow 200 representing exampleoperations related to accepting at least one attribute of at least oneindividual, querying at least one database at least partly based on theat least one attribute, selecting from the at least one database atleast one prescription medication and at least one artificial sensoryexperience to address the at least one attribute of at least oneindividual, and/or presenting an indication of the at least oneprescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. In FIG. 2 and in following figures that includevarious examples of operational flows, discussion and explanation may beprovided with respect to the above-described examples of FIG. 1, and/orwith respect to other examples and contexts. However, it should beunderstood that the operational flows may be executed in a number ofother environments and contexts, and/or in modified versions of FIG. 1.Also, although the various operational flows are presented in thesequence(s) illustrated, it should be understood that the variousoperations may be performed in other orders than those which areillustrated, or may be performed concurrently.

After a start operation, the operational flow 200 moves to an operation210. Operation 210 depicts accepting at least one attribute of at leastone individual. For example, as shown in FIG. 1, acceptor module 102 mayaccept at least one attribute of at least one individual. In oneinstance, acceptor module 102 can accept from a user 118 and a userinterface 116 an attribute 120 including an attribute of a personalhealth history associated with an individual named John Smith. In someinstances, acceptor module 102 may include a computer processor.

Then, operation 220 depicts querying at least one database at leastpartly based on the at least one attribute. For example, as shown inFIG. 1, querier module 104 may search at least one database at leastpartly based on the at least one attribute. In one example andcontinuing with the previous example, querier module 104 can search adatabase 122 including a medication database 124 and artificial sensoryexperience database 126 at least partly based on the attribute includingan attribute of a personal health history associated with an individualnamed John Smith. In some instances, querier module 104 may include acomputer processor.

Then, operation 230 depicts selecting from the at least one database atleast one prescription medication and at least one artificial sensoryexperience to address the at least one attribute of at least oneindividual. For example, as shown in FIG. 1, selector module 106 mayselect from the at least one database at least one prescriptionmedication and at least one artificial sensory experience to address theat least one attribute of at least one individual. In one instance andcontinuing with the previous example, selector module 106 can selectfrom a medication database 124 and artificial sensory experiencedatabase 126 a prescription medication and an artificial sensoryexperience for addressing the attribute 120 including an attribute of apersonal health history associated with an individual named John Smith.In some instances, selector module 106 may include a computer processor.

Then, operation 240 depicts presenting an indication of the at least oneprescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. For example, as shown in FIG. 1, presentermodule 108 may present the at least one prescription medication and theat least one artificial sensory experience at least partly based on thesearching at least one database at least partly based on the at leastone attribute. In one instance and continuing with the previous example,presenter module 108 can present to a medical professional theprescription medication and the artificial sensory experience based onsearching the medication database 124 and artificial sensory experiencedatabase 126 based on the at least one attribute 120 including anattribute of a personal health history associated with an individualnamed John Smith. In some instances, presenter module 108 may include acomputer processor.

FIG. 3 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 3 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 302.

Operation 302 illustrates accepting at least one physical enhancementgoal associated with the at least one individual. For example, as shownin FIG. 1, acceptor module 102 may accept from a database entry 114 atleast one physical enhancement goal associated with the at least oneindividual. In one instance and continuing with the above example,acceptor module 102 accepts from memory device 112 at least one physicalenhancement goal associated with an individual named John Smith. Aphysical enhancement goat may include a physical state and/or situationan individual may plan to achieve. Some examples of a physicalenhancement goal may include achieving a certain state of relaxation,reaching a certain body mass, maintaining a specific cholesterol level,achieving an athletic performance goal, and/or lowering a blood pressurelevel. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 4 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 4 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 402, an operation 404, and/or anoperation 406.

Operation 402 illustrates accepting at least one physical attributeassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept from network storage 110 at leastone physical attribute associated with the at least one individual. Inone instance, acceptor module 102 can accept a physical attribute 120associated with a group of twenty individuals including an individualweight for each individual. A physical attribute may include anattribute that may be described and/or detected using senses, that hassubstance and/or a material existence, and/or that may be acted upon byphysical force. Some examples of a physical attribute may include abiochemical measurement such as blood sugar level, a smell, anappearance, a physiological measurement such as blood pressure, and/orskin conductivity. In some instances, acceptor module 102 may include acomputer processor.

Operation 404 illustrates accepting at least one physical symptomassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one physical symptomassociated with the at least one individual. In one example, acceptormodule 102 can accept from a user 118 and/or user interface 116 aphysical symptom including an indication of influenza such as a feverassociated with an individual named Mark White. A physical symptom mayinclude a manifestation, sign, and/or an indication of the presence of adisease and/or some other bodily disorder and/or abnormality. Someexamples of a physical symptom may include pain, swelling, fever, rash,and/or discoloration. In some instances, acceptor module 102 may includea computer processor.

Operation 406 illustrates accepting at least one of an indication or ameasurement of at least one of pain, hypertension, sweating, dizziness,lightheadedness, abnormal respiration, headache, fatigue, nausea, fever,abnormal heart rhythm, motor weakness, or abnormal heart rate. Forexample, as shown in FIG. 1, acceptor module 102 may accept from atleast one of an indication or a measurement of at least one of pain,high blood pressure, sweating, dizziness, lightheadedness, abnormalrespiration, headache, fatigue, nausea, fever, abnormal heart rhythm,motor weakness, or abnormal heart rate. In one example, acceptor module102 can accept an indication of pain and a measurement of high bloodpressure from network storage 110. Pain may include a sensation ofsomatic hurt or disorder and may include acute pain and/or chronic pain.Hypertension may include chronically elevated blood pressure and may becontinued to be present when a person's systolic blood pressure isconsistently about 140 mm Hg or greater and/or their diastolic bloodpressure is consistently about 90 mm Hg or greater. Sweating may includethe excessive production and/or evaporation of fluid excreted by thesweat glands in the skin. Dizziness may include vertigo, disequilibrium,pre-syncope, and/or other balance disorders. Lightheadedness may includea sensation of dizziness and/or fainting. Abnormal respiration mayinclude atypical and/or pathological breathing patterns. Headache mayinclude pain in the head, neck, and/or upper back and may be a symptomof tension, migraine, dehydration, eye strain, sinus disorders, and/orlow blood sugar. Fatigue may include muscle weakness and/or lack ofstrength. Nausea may include the sensation of unease and/or discomfortin the stomach, often with the urge to vomit. Fever may include anincrease in internal body temperature to levels above normal. Abnormalheart rhythm may include inconsistent and/or irregular rhythmiccontractions in the heart such as sick sinus syndrome, atrialfibrillation, and/or atrial flutter. Motor weakness may include a lackof strength and/or function in the portion of the central nervous systeminvolved in movement. An abnormal heart rate may include an irregularheart contraction frequency such as bradycardia, tachycardia or thelike. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 5 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 5 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 502, and/or an operation 504.Further, operation 502 illustrates accepting at least one physicalimpairment associated with the at least one individual. For example, asshown in FIG. 1, acceptor module 102 may accept at least one physicalimpairment associated with the at least one individual from a user 118and a user interface 116. In one instance, acceptor module 102 accepts aphysical impairment including a bodily impairment associated with anindividual named Fred Johnson from a user 118 and/or a user interface116. A physical impairment may include a condition or function judged tobe significantly impaired relative to the usual standard of anindividual of their group and may include physical impairment, sensoryimpairment, and/or disease. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 504 illustrates accepting at least one of a disease, anillness, or a bodily impairment. For example, as shown in FIG. 1,acceptor module 102 may accept at least one of a disease, an illness, ora bodily impairment. In one example, acceptor module 102 accepts anindication of a disease and a bodily impairment from database entry 114.A disease may include an abnormal condition of an organism that impairsbodily functions associated with one or more specific symptoms and signsand may include discomfort, distress, dysfunction, injury, a disorder, asyndrome, infection, and/or other atypical variation associated withstructure and/or function of the body. An illness may include any stateof poor health. Some examples of an illness may include cancer, thecommon cold, influenza, pneumonia, and/or high cholesterol. A bodilyimpairment may include a diminished ability in body function and/orstructure. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 6 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 6 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 602. Operation 602 illustratesaccepting an impairment associated with at least one individualincluding at least one of a potential medication reaction or a potentialsusceptibility to a side effect. For example, as shown in FIG. 1,acceptor module 102 may accept an impairment associated with at leastone individual including at least one of a potential medication reactionor a potential susceptibility to a side effect. In one example, acceptormodule 102 can accept from network storage 110 an impairment associatedwith at least one individual including at least one of a potentialmedication reaction or a potential susceptibility to a side effect. Apotential medication reaction may include a possible response a personmay exhibit resulting from at least one drug and/or medicationadministered to the person. A potential medication reaction may includean allergy and/or a drug and/or medication interaction with a separatedrug and/or medication. A potential susceptibility to a side effect mayinclude the probability a certain person may be vulnerable to a sideeffect coupled with a specific drug and/or medication. In someinstances, acceptor module 102 may include a computer processor.

FIG. 7 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 7 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 702, and/or an operation 704.Further, operation 702 illustrates accepting at least one physicaldiagnosis associated with the at least one individual. For example, asshown in FIG. 1, acceptor module 102 may accept at least one physicaldiagnosis associated with the at least one individual. In a specificexample, acceptor module 102 accepts from memory device 112 a physicaldiagnosis associated with a group of ten individuals. A physicaldiagnosis may include identifying a disease and/or condition by itsoutward signs and/or symptoms. Some examples of a physical diagnosis mayinclude identifying influenza and/or identifying Alzheimer's disease. Insome instances, acceptor module 102 may include a computer processor.

Operation 704 illustrates accepting at least one diagnosis of at leastone of a cardiovascular disorder, a digestive disorder, an endocrinedisorder, a hearing disorder, an immune disorder, an inner ear disorder,an integumentary disorder, a lymphatic disorder, a muscular disorder, anervous system disorder, a reproductive disorder, a respiratorydisorder, a skeletal disorder, a visual disorder, or an urinarydisorder. For example, as shown in FIG. 1, acceptor module 102 mayaccept at least one diagnosis of at least one of a cardiovasculardisorder, a digestive disorder, an endocrine disorder, an integumentarydisorder, a lymphatic disorder, a muscular disorder, a nervous systemdisorder, a reproductive disorder, a respiratory disorder, a skeletaldisorder, or an urinary disorder. In a specific instance, acceptormodule 102 can accept from user interface 116 and/or user 118 adiagnosis of a respiratory disorder. A cardiovascular disorder mayinclude a disorder associated with the circulatory system including thepumping and channeling of blood to and from the body and lungs with theheart, the blood, and the blood vessels. Examples of a circulatorydisorder include high blood pressure, coronary heart disease,atherosclerosis, or the like. A digestive disorder may include adisorder associated with the esophagus, the stomach, the liver, thegallbladder, the pancreas, the intestines, the rectum, the anus, and/orthe digestive system including digestion and processing food withsalivary glands. Examples of a digestive disorder include GERD, Crohn'sdisease, IBS, stomach ulcers including those associated with H. pyloriinfection, or the like. An endocrine disorder may include a disorderassociated with the endocrine system including the pancreas, thepituitary gland, the pineal body and/or the pineal gland, the thyroid,the parathyroids, the adrenal glands, and/or communication within thebody using hormones made by the endocrine glands, such as thehypothalamus. Examples of an endocrine disorder include diabetes,acromegaly, or the like. A hearing disorder may include a full orpartial decrease in the ability to detect or understand sounds. Someexamples of a hearing disorder may include otosclerosis, deafness, lossdue to death of auditory hair cells, for example that caused by trauma,and/or unilateral hearing toss. An immune disorder may include adysfunction of the immune system. Examples of an immune disorder mayinclude an immunodeficiency, such as malfunctioning lymphocytes;autoimmunity, such as Coeliac disease and/or autoimmune hepatitis;and/or hypersensitivity, such as asthma. An inner ear disorder mayinclude a balance disorder, such as vertigo, disequilibrium, and/orpre-syncope. An integumentary disorder may include a disorder associatedwith the integumentary system including the skin, hair, and/or nails,such as psoriasis, eczema, dermatitis, or the like. A lymphatic disordermay include a disorder associated with the lymphatic system includingstructures involved in the transfer of lymph between tissues and theblood stream and/or the lymph and the nodes and vessels that transportlymph including the immune system, including defending againstdisease-causing agents with leukocytes, and/or including the tonsils,the adenoids, the thymus, and/or the spleen. Examples of a lymphaticdisorder include lymphedema, lymphadenopathy, or the like. A muscledisorder may include a disorder associated with the muscular systemincluding the structure and/or movement of muscles. Examples of a muscledisorder include muscular dystrophy, myasthenia gravis, an injury, suchas a strain, or the like. A nervous system disorder may include adisorder associated with the nervous system including collecting,transferring, and/or processing information with the brain, the spinalcord, the peripheral nerves, and/or the nerves. Examples of a nervoussystem disorder include multiple sclerosis, fibromyalgia, carpal tunnelsyndrome, or the like. A reproductive disorder may include a disorderassociated with the reproductive system including the sex organs, suchas ovaries, fallopian tubes, the uterus, the vagina, mammary glands,testes, the vas deferens, seminal vesicles, the prostate, and/or thepenis. Examples of a reproductive disorder include erectile dysfunction,endometriosis, fibroids, or the like. A respiratory disorder may includea disorder associated with the respiratory system including the organsused for breathing, the pharynx, the larynx, the trachea, the bronchi,the lungs, and/or the diaphragm. Examples of a respiratory disorderinclude emphysema, asthma, or the like. A skeletal disorder may includea disorder associated with the skeletal system including the structuralsupport and protection with bones, cartilage, ligaments, and/or tendons.Examples of a skeletal disorder include osteoporosis, arthritis,tendonitis, a skeletal injury, such as a bone fracture, or the like. Avisual disorder may include a disease, impairment, and/or lack offunction in the eye and/or in visual perception. Some examples of avisual disorder may include amblyopia, macular degeneration, glaucoma,and/or blindness. A urinary disorder may include a disorder associatedwith the urinary system including the kidneys, the ureters, the bladderand/or urethra involved in fluid balance, electrolyte balance and/or theexcretion of urine. Examples of a urinary disorder include bladderdysfunction, kidney disease, bladder or urethra infection, or the like.In some instances, acceptor module 102 may include a computer processor.

FIG. 8 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 8 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 802, an operation 804, an operation806, and/or operation 808.

Operation 802 illustrates accepting at least one of a current treatmentor a proposed treatment associated with the at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept at least oneof a current treatment or a proposed treatment associated with the atleast one individual. In one instance, acceptor module 102 accepts acurrent treatment regime associated with an individual named CathyHansen. A current treatment may include one or a series of treatmentsrecommended, administered, and/or prescribed for a certain individual. Aproposed treatment may include one or a series of treatmentsrecommended, prescribed, and/or not currently administered to a certainindividual. In some instances, acceptor module 102 may include acomputer processor.

Operation 804 illustrates accepting the at least one attribute from amedical history associated with the at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept the at leastone attribute from a medical history associated with the at least oneindividual. In one example, acceptor module 102 may accept from databaseentry 114 an attribute 120 from a medical history including the numberof blood relatives with diabetes associated with an individual namedEmily Smith. A medical history may include a list of previous illnesses,symptoms, medicines, treatments, health risk factors, operations, and/ordoctor visits for an individual and/or a relation of an individual. Insome instances, acceptor module 102 may include a computer processor.

Operation 806 illustrates accepting the at least one attribute from apersonal medical history associated with at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept the at leastone attribute from a personal medical history associated with at leastone individual. In a specific instance, acceptor module 102 can acceptfrom database entry 114 an attribute 120 including, for example, a listof operations from a personal medical history associated with anindividual named Robert Murphy. A personal medical history may include alist of previous illnesses, symptoms, medicines, treatments, health riskfactors, operations, and/or doctor visits associated with at least oneindividual. A personal and/or a family medical history may include lifehistory and/or social history characteristics such as smoking, drinking,drug use, sexual history, exercise history, eating history,nutraceutical history, or the like. In some instances, acceptor module102 may include a computer processor.

Operation 808 illustrates accepting the at least one attribute from afamily medical history associated with the at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept the at leastone attribute from a family medical history associated with the at leastone individual. In one example, acceptor module 102 can accept fromnetwork storage 110 an attribute 120 including a list of family membersthat have had ovarian cancer from a family medical history associatedwith an anonymous individual or an individual named Elizabeth Green. Afamily medical history may include a list of previous illnesses,symptoms, medicines, treatments, health risk factors, operations, and/ordoctor visits associated with family members related to the at least oneindividual. In some instances, acceptor module 102 may include acomputer processor.

FIG. 9 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 9 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 902.

Operation 902 illustrates accepting at least one mental enhancement goalassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one mental enhancementgoal associated with the at least one individual. In one instance,acceptor module 102 can accept a mental enhancement goal associatedwith, for example, an individual named Dorothy Anderson. A mentalenhancement goat may include a mental state and/or situation anindividual may plan to achieve. Some examples of a mental enhancementgoat may include achieving a certain state of mental awareness such asincreased alertness or visual perception, reaching a certain cognitivecapability such as enhanced memory or pattern recognition, maintaining aspecific attention level, and/or reducing or eliminating a phobia. Insome instances, acceptor module 102 may include a computer processor.

FIG. 10 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 10 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1002, an operation 1004, and/or anoperation 1006.

Operation 1002 illustrates accepting at least one mental attributeassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one mental attributeassociated with the at least one individual. In one example, acceptormodule 102 can accept a mental attribute 120 including, for example, anintelligence quotient associated with an individual named Judy Peterson.A mental attribute may include an attribute that may be related toand/or associated with basic mental function and/or high-level brainfunction. Some examples of a mental attribute may include anintelligence quotient (IQ), measurements of brain activity for exampleusing functional MRI or near infra-red technology, and/or measurementsof mental development. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 1004 illustrates accepting at least one mental symptomassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one mental symptomassociated with the at least one individual. In one example, acceptormodule 102 can accept from network storage 110 a mental symptomincluding a stress level measurement associated with an individual namedHeather Swanson. A mental symptom may include a manifestation, sign,and/or an indication of the presence of a disease and/or some othermental disorder and/or abnormality. Some examples of a mental symptommay include lack of attention, indication of stress, hyperactivity,nervousness, and/or lack of responsiveness. In some instances, acceptormodule 102 may include a computer processor.

Operation 1006 illustrates accepting at least one indication of anxiety,an appearance, a behavior, depression, fear, inattention, a mooddisturbance, a phobia, or a psychological test result. For example, asshown in FIG. 1, acceptor module 102 may accept at least one indicationof anxiety, appearance, behavior, depression, fear, inattention, mooddisturbance, phobia, or psychological test result. In one example,acceptor module 102 can accept from user interface 116 and user 118 anindication of anxiety and depression. Anxiety may include feelings offear, apprehension, and/or worry and may be accompanied by physicalsensations. An appearance may include an outward, audible, and/orvisible aspect of a person and/or thing associated with a person. Abehavior may include the manner in which a person and/or thingassociated with a person acts and/or reacts. Depression may include amental state characterized by pessimism, a sense of inadequacy,despondence, despair, a low level of energy, and/or a lack of activity.Fear may be caused by impending danger, perceived evil, and/or pain,whether real or imagined. Inattention may include the failure of aperson to focus attention. A mood disturbance may include a change inemotional state. A phobia may include an irrational, and/or persistentfear of certain situations, objects, activities, and/or people. Apsychological test result may include a sample behavior for inferring acertain generalization about a person. For example, a personality testresult may indicate that person has obsessive/compulsivecharacteristics. In some instances, acceptor module 102 may include acomputer processor.

FIG. 11 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 11 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1102.

Operation 1102 illustrates accepting at least one measurement associatedwith at least one of brain activity, cardiac activity, vascularactivity, peripheral neural signals, hemodynamic activity, or metabolicactivity. For example, as shown in FIG. 1, acceptor module 102 mayaccept at least one measurement associated with at least one of brainactivity, cardiac activity, vascular activity, peripheral neuralsignals, hemodynamic activity, or metabolic activity. In one instance,acceptor module 102 can accept from database entry 114 a measurementassociated with brain activity. Brain activity may include theelectrical activity of the brain, such as that measured by EEG, MEG, orthe like. Other brain activity measurements may include functional MRIimaging, near infra-red imaging, PET scanning, or the like. Cardiacactivity may include electrical activity in the heart, such as thatmeasured by EKG or visual imaging. Vascular activity may include anyactivity and/or function of the circulatory system. Peripheral neuralsignals may include neural signals sent through the peripheral nervoussystem. Hemodynamic activity may include any activity associated withthe circulatory system. Metabolic activity may include any activityassociated with the biochemical reactions occurring in a livingorganism. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 12 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 12 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1202, and/or an operation 1204.

Operation 1202 illustrates accepting at least one mental impairmentassociated with at least one individual. For example, as shown in FIG.1, acceptor module 102 may accept at least one mental impairmentassociated with at least one individual. In one example, acceptor module102 can accept from memory device 112 a mental impairment associatedwith an individual named Richard Lewis. A mental impairment may includea condition or function judged by a health care provider to besignificantly impaired relative to the usual standard of an individualof their group, and may include mental impairment, sensory impairment,and/or mental disease. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 1204 illustrates accepting at least one indication of at leastone of a mood disorder, an anxiety disorder, a psychotic disorder, aneating disorder, a developmental disorder, a phobia, a communicationdisorder, a social disorder, or a personality disorder. For example, asshown in FIG. 1, acceptor module 102 may accept at least one indicationof at least one of a mood disorder, an anxiety disorder, a psychoticdisorder, an eating disorder, a developmental disorder, a phobia, or apersonality disorder. In one instance, acceptor module 102 can acceptfrom user interface 116 and/or user 118 an indication of a mood disorderincluding a mood change and the onset of depression in a specificindividual. A mood disorder may include a condition whereby theprevailing emotional mood is distorted or inappropriate to thecircumstances, and may include examples such as bipolar disorder, analteration in mood, and/or depression. An anxiety disorder may includenervous system disorders such as irrationality, illogical worry notbased on fact, fear, and/or phobia. A psychotic disorder may include astate of mind in which thinking becomes irrational and/or disturbed andmay include hallucinations, abnormal perception, mania, dementia,delusions and/or delusional beliefs, delirium, depression, psychosispersonality disorder, personality changes, and/or disorganized thinking.An eating disorder may include a compulsion to eat and/or avoid eatingthat negatively affects physical and/or mental health. Some examples ofan eating disorder may include anorexia nervosa and bulimia nervosa. Adevelopmental disorder may include a disorder occurring in a child'sdevelopment, which may retard development. Some examples of adevelopmental disorder may include an emotional disorder, a cognitivedisorder, and/or a mental disorder accompanied by physical traits, suchas Down syndrome. A phobia may include an irrational, intense, and/orpersistent fear of certain situations, objects, activities, and/orpersons. Examples of phobias include social phobias, arachnophobia,xenophobia, and/or claustrophobia. A communication disorder may includea disease and/or a condition partially or totally preventing humancommunication. Some examples of a communication disorder may includeautism, stuttering, and/or aphasia. A social disorder may include acondition characterized by a difficulty in human interaction and/oremotional discomfort in social situations. Some examples of a socialdisorder may include stage fright, social anxiety disorder, and/orshyness. A personality disorder may include a disorder characterized bypathological trends in personality structure. Some examples of apersonality disorder may include a paranoid personality disorder, anarcissistic personality disorder, and/or an obsessive-compulsivepersonality disorder. In some instances, acceptor module 102 may includea computer processor.

FIG. 13 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 13 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1302, and/or an operation 1304.Further, operation 1302 illustrates accepting at least one mentaldiagnosis associated with at least one individual. For example, as shownin FIG. 1, acceptor module 102 may accept at least one mental diagnosisassociated with at least one individual. In a specific instance,acceptor module 102 accepts from memory device 112 a mental diagnosisincluding a phobia associated with an anonymous individual or anindividual named Roy Black. A mental diagnosis may include identifying amental disorder and/or condition by its symptoms. Some examples of amental diagnosis may include a mood disorder such as depression, ananxiety disorder such as PTSD, a behavioral disorder such as ADHD, apersonality disorder such as borderline personality disorder, and/or aphobia. Mental disorders may include those listed in the Diagnostic andStatistical Manual of Mental Disorders (DSM). In some instances,acceptor module 102 may include a computer processor.

Operation 1304 illustrates accepting at least one of a depression, aphobia, an anxiety disorder, a personality disorder, a psychoticdisorder, a developmental disorder, a panic disorder, a bipolardisorder, schizophrenia, an eating disorder, obsessive compulsivedisorder, post traumatic stress disorder, an attentional disorder, acommunication disorder, a social disorder, or a mood disorder. Forexample, as shown in FIG. 1, acceptor module 102 may accept at least oneof a depression, a phobia, an anxiety disorder, a personality disorder,a psychotic disorder, a developmental disorder, a panic disorder, or amood disorder. In one example, acceptor module 102 accepts from databaseentry 114 a diagnosis of depression. Depression may include a mentalstate characterized by a pessimistic sense of inadequacy and/or adespondent lack of activity. A phobia may include an irrational,intense, and/or persistent fear of certain situations, objects,activities, and/or persons. Some phobias may include social phobias,arachnophobia, xenophobia, and/or claustrophobia. An anxiety disordermay include nervous system disorders such as irrationality, illogicalworry not based on fact, fears, and/or phobias. A personality disordermay include a disorder characterized by pathological trends inpersonality structure. Some examples of a personality disorder mayinclude a paranoid personality disorder, a narcissistic personalitydisorder, and/or an obsessive-compulsive personality disorder. Apsychotic disorder may include a state of mind in which thinking becomesirrational and/or disturbed and may include hallucinations, delusionalbeliefs, personality changes, and/or disorganized thinking. Adevelopmental disorder may include a disorder occurring in a child'sdevelopment, which may often retard development. Some examples of adevelopmental disorder may include psychological or physical disorders.A panic disorder may include a condition characterized by recurringpanic attacks in combination with significant behavioral change. Abipolar disorder may include a mood disorder characterized by thepresence of one or more episodes of abnormally elevated mood, such asBipolar I disorder, Bipolar II disorder, cyclothymia, and/orBipolar-NOS. Schizophrenia may include a mental illness characterized byimpairments in the perception or expression of reality, most commonlymanifesting as auditory hallucinations, paranoid or bizarre delusions ordisorganized speech and thinking in the context of significant social oroccupational dysfunction. An eating disorder may include a compulsion toeat or avoid eating, such as anorexia nervosa and/or bulimia nervosa.Obsessive compulsive disorder may include a psychiatric anxiety disordercharacterized by obsessive, distressing, intrusive thoughts and relatedcompulsions which attempt to neutralize the obsessions. Post traumaticstress disorder may include an anxiety disorder that can develop afterexposure to one or more terrifying events in which grave physical harmoccurred or was threatened. An attentional disorder may include apersistent pattern of inattention and/or hyperactivity, as well asforgetfulness, poor impulse control or impulsivity, and distractibility,such as attention-deficit hyperactivity disorder (ADHD). A communicationdisorder may include a disease and/or a condition partially or totallypreventing human communication. Some examples of a communicationdisorder may include autism, stuttering, and/or aphasia. A socialdisorder may include a condition characterized by a difficulty in humaninteraction and/or emotional discomfort in social situations. Someexamples of a social disorder may include stage fright, social anxietydisorder, and/or shyness. A mood disorder may include a conditionwhereby the prevailing emotional mood is distorted or inappropriate tothe circumstances and may include examples such as bipolar disorderand/or depression. In some instances, acceptor module 102 may include acomputer processor.

FIG. 14 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 14 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1402. Further, operation 1402illustrates accepting at least one past mental therapy associated withthe at least one individual. For example, as shown in FIG. 1, acceptormodule 102 may accept at least one past mental therapy associated withthe at least one individual. In one instance, acceptor module 102 canaccept from database entry 114 a past mental therapy associated with anindividual named James Williams or an anonymous individual. A pastmental therapy may include a list and/or a record of at least one mentaltherapy, such as an anti-depressant medication, administered to at leastone individual. In some instances, acceptor module 102 may include acomputer processor.

FIG. 15 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 15 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1502, an operation 1504, and/or anoperation 1506.

Operation 1502 illustrates accepting the at least one attributeassociated with the at least one individual from a health care provider.For example, as shown in FIG. 1, acceptor module 102 may accept the atleast one attribute associated with the at least one individual from ahealth care provider. In one example, acceptor module 102 can acceptfrom user interface 116 and/or user 118 an attribute 120 including amedication history associated with a group of fifty individuals from ahealth care provider 136. A health care provider may include a hospital,a doctor, a nurse, a medical clinic, a dentist, and/or any provider ofpreventive, diagnostic, therapeutic, rehabilitative, maintenance, orpalliative care and/or counseling. A healthcare provider may include aseller and/or dispenser of prescription drugs or medical devices. Insome instances, acceptor module 102 may include a computer processor.

Operation 1504 illustrates accepting the at least one attributeassociated with the at least one individual from a licensed health careprovider. For example, as shown in FIG. 1, acceptor module 102 mayaccept the at least one attribute associated with the at least oneindividual from a licensed health care provider. In one instance,acceptor module 102 accepts from memory device 112 an attribute 120including a symptom indication a phobia associated with an individualnamed Robert Clark from a licensed health care provider 136. A licensedhealth care provider may include a person licensed by a governingauthority, such as a state, to provide medical and/or health care. Someexamples of a licensed health care provider may include a licensedmedical doctor or physician, a licensed physician's assistant, and/or alicensed nurse practitioner. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 1506 illustrates accepting the at least one attributeassociated with the at least one individual from an alternative medicineprovider. For example, as shown in FIG. 1, acceptor module 102 mayaccept the at least one attribute associated with the at least oneindividual from an alternative medicine provider. In one instance,acceptor module 102 can accept from network storage 110 an attribute 120associated with an individual named Connie Martin from an alternativemedicine provider. An alternative medicine provider may include aprovider of folk medicine, herbal medicine, diet fads, homeopathy, faithhealing, new age healing, chiropractic, acupuncture, aromatherapy,naturopathy, massage, reflexology, hypnotism, and/or music therapy. Insome instances, acceptor module 102 may include a computer processor.

FIG. 16 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 16 illustrates example embodiments whereoperation 220 may include at least one additional operation. Additionaloperations may include an operation 1602.

Operation 1602 illustrates searching at least one prescriptionmedication database and at least one artificial sensory experiencedatabase. For example, as shown in FIG. 1, querier module 104 may searchat least one prescription medication database and at least oneartificial sensory experience database. In one example, querier module104 searches a medication database 124 and an artificial sensoryexperience database 126. A database may include a collection of dataorganized for convenient access. The database may include informationdigitally stored in a memory device 112, as at least a portion of atleast one database entry 114, and/or in network storage 110. In someinstances, the database may include information stored non-digitallysuch as at least a portion of a book, a paper file, and/or anon-computerized index and/or catalog. Non-computerized information maybe received by acceptor module 102 by scanning or by manually enteringthe information into a digital format. A prescription database and/ormedication database may include any database associated with at leastone prescription medication and may be available to health careprofessionals and/or the public. An artificial sensory experiencedatabase may include any database associated with at least oneartificial sensory experience and may include a database accessible bythe public and/or a health care provider. In some instances, acceptormodule 102 and/or querier module 104 may include one or more computerprocessors.

FIG. 17 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 17 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 1702, and/or an operation 1704.

Operation 1702 illustrates selecting the at least one prescriptionmedication from a physician's desk reference database. For example, asshown in FIG. 1, selector module 106 may select the at least oneprescription medication from a physician's desk reference database. Inone example, selector module 106 selects the at least one prescriptionmedication from a physician's desk reference database 122, such as a PDRpsychiatry database. In some instances, selector module 106 may includea computer processor.

Operation 1704 illustrates selecting at least one of an analgesic, anantacid, an antiarrhythmic, an antibacterial, an antibiotic, ananticoagulant, a thrombolytic, an anticonvulsant, an antidiarrheal, anantiemetic, an antifungal, an anti-allergic agent, an antihistamine, anantihypertensive, an anti-anginal, an anti-asthmatic, ananti-inflammatory, an antineoplastic, an antipyretic, an antiviral, ananti-ulcer agent, an antidyspeptic, an antacid, a beta-blocker, abronchodilator, a cold treatment, a corticosteroid, an antitussive, acytotoxic agent, a decongestant, a diuretic, an expectorant, a hormone,a hypoglycemic, an immunosuppressive, a laxative, a muscle relaxant, asedative, a female sex hormone, a male sex hormone, a tranquilizer, anappetite modulator, or a vitamin. For example, as shown in FIG. 1,selector module 106 may select at least one of an analgesic, an antacid,an antiarrhythmic, an antibacterial, an antibiotic, an anticoagulant, athrombolytic, an anticonvulsant, an antidiarrheal, an antiemetic, anantifungal, an anti-allergic agent, an antihistamine, anantihypertensive, an anti-anginal, an anti-asthmatic, ananti-inflammatory, an antineoplastic, an antipyretic, an antiviral, ananti-ulcer agent, an antidyspeptic, an antacid, a beta-blocker, abronchodilator, a cold treatment, a corticosteroid, a cough suppressant,an antitussive, a cytotoxic agent, a decongestant, a diuretic, anexpectorant, a hormone, a hypoglycemic, an immunosuppressive, alaxative, a muscle relaxant, a sedative, a female sex hormone, a malesex hormone, a tranquilizer, an appetite modulator, or a vitamin. Ananalgesic may include a drug and/or other medication suitable forrelieving pain. Additionally, an analgesic may be effective forrelieving different degrees of pain. Some examples of an analgesic mayinclude narcotics such as morphine or oxycodone, non-narcotics, an NSAIDsuch as aspirin or naproxen or ibuprofen, and/or acetaminophen. Anantacid may include a substance for neutralizing stomach acid, such as aproton pump inhibitor. Some examples of an antacid may includeimeprazole and/or a pharmaceutical composition containing aluminumhydroxide, magnesium hydroxide, aluminum carbonate, calcium carbonate,sodium bicarbonate, hydrotalcite, bismuth subsalicylate, magaldrate,and/or simethicone.

An antiarrhythmic may include a drug for controlling a heartbeatirregularity. Some examples of an antiarrhythmic may include a betablocker such as propanolol, and/or lidocaine, verapamil, and/orquinidine. An antibacterial may include a drug used to treat aninfection. Some examples of an antibacterial may include amoxicillinand/or ciprofloxacin. An antibiotic may include a drug made fromnaturally occurring and/or synthetic substances for combating abacterial infection. Some examples of an antibiotic may includepenicillin, streptomycin, and/or sulfonamide-based drugs. Ananticoagulant may include an agent for preventing blood clots. Anexample of an anticoagulant may include a vitamin K antagonist, such aswarfarin, and/or aspirin. A thrombolytic may help dissolve and dispersea blood clot and may be prescribed for patients with recent arterial orvenous thrombosis. A thrombolytic may be derived from Streptomyces spp.and/or recombinant DNA technology and may include streptokinase,urokinase, and/or a tissue plasminogen activator (TPA) such asalteplase.

An anticonvulsant may include a pharmaceutical administered for theprevention of seizures. Some examples of an anticonvulsant may include abarbiturate, a carbamate, a fatty acid derivative, and/or a sulfonamide.An antidiarrheal may include a drug utilized for the relief of diarrhea.Some examples of an antidiarrheal may include an antispasmodic such asdiphenoxylate and loperamide, a bismuth compound, a bulking agent,and/or an absorbent. An antiemetic may include a drug used to treatnausea and vomiting. Some examples of an antiemetic may include a 5-HT3receptor antagonist, a dopamine antagonist, and/or a histamine. Anantifungal may include a drug used to treat fungal infections, the mostcommon of which affect the hair, skin, nails, and/or mucous membranes.Some examples of antifungals may include polyene antifungals, imidazoleand triazole antifungals, and/or allylamines. An anti-allergenic agentmay include an agent characterized by preventing and/or reducing theeffect of an allergen. Some examples of an anti-allergenic may includean antihistamine, cortisone, hydrocortisone, and/or epinephrine. Anantihistamine may include an agent used for counteracting the effects ofhistamine. Some examples of an antihistamine may include a H1-receptorantagonist and/or a H2-receptor antagonist. An antihypertensive mayinclude drugs utilized for towering blood pressure. Some examples of anantihypertensive may include a diuretic, an adrenergic receptorantagonist, and/or an ACE inhibitor. An anti-anginal may include anagent used for preventing and/or reducing angina and/or chest pain. Someexamples of an anti-anginal may include aspirin, ranolazine, and/orivabradine. An anti-asthmatic may include an agent for preventing and/orreducing asthma and/or its effects. Some examples of an anti-asthmaticmay include albuterol, an inhaled steroid, for example budesonide orfluticasone, and/or ipratropium bromide.

An anti-inflammatory may include an agent utilized to reduceinflammation and/or to treat redness, heat, swelling, and/or increasedblood flow associated for example, that seen with an infection orinjury, or in many chronic diseases such as rheumatoid arthritis andgout. Some anti-inflammatories may include steroids, and/or NSAIDs suchas naproxen, ibuprofen, and/or aspirin. An antineoplastic may includedrugs used to treat cancer and to inhibit and/or prevent the developmentof tumors. Some antineoplastics may include alkylating agents,antimetabolites, enzymes, enzyme inhibitors, immune modulators, andtaxoids. An antipyretic may include a drug used to reduce a fever. Someexamples of an antipyretic may include aspirin and/or acetaminophen. Anantiviral may include a drug used to treat viral infections and/or toprovide temporary protection against viral infections such as influenza.Some examples of an antiviral may include an interferon, acyclovir,ribavirin, and/or osettamivir. An anti-ulcer agent may include an agentused for preventing and/or lessening the effect of an ulcer, includingstomach ulcers, mouth ulcers, or other types of ulcers. Some examples ofan anti-ulcer agent may include a bismuth compound, a prostaglandinanalogue, and/or cimetidine. An antidyspeptic may include an agent usedfor treating and/or preventing dyspepsia. Some examples of anantidyspeptic may include simethicone and/or a proton pump inhibitor,such as esomeprazote. An antacid may include a substance, often a base,which may counteract stomach acidity. Some examples of an antacid mayinclude magnesium hydroxide, aluminum hydroxide, calcium carbonate,and/or bismuth subsalicylate. A beta-blocker may include abeta-adrenergic blocking agent utilized for reducing the oxygen needs ofthe heart by reducing the heartbeat rate. Some examples of abeta-blocker may include propranolol, esmolol, bisoprolol, and/ortimolol. A bronchodilator may include an agent utilized for opening thebronchial tubes within the lungs when the tubes have become narrowed,for example, by muscle spasm and may be used for treating asthma. Someexamples of a bronchodilator may include albuterol and/or ipratropiumbromide. A cold treatment may include an agent utilized for treatingaches, pains, and/or fever accompanying a cold. Some cold treatments mayinclude aspirin, acetaminophen, a decongestant, an antihistamine, and/orcaffeine.

A corticosteroid may include a hormonal preparation used as ananti-inflammatory for arthritis or asthma and/or treating somemalignancies or compensating for a deficiency of natural hormones. Someexamples of a corticosteroid may include cortisol and/or aldosterone. Acough suppressant may include an agent used to soothe irritation causedby coughing and/or to prevent coughing. Some examples of a coughsuppressant may include codeine, an antihistamine, and/ordextromethorphan. An antitussive may include a cough suppressant. Acytotoxic agent may include a drug used for killing and/or damagingcells. Some examples of a cytotoxic agent may include actinomycin-D,azathioprine, bleomycin, melphalan, busulphan, doxorubicin, etoposide,an antineoplastic agent, and/or an apoptotic agent. A decongestant mayinclude an agent for reducing the swelling of the mucous membraneslining the nose and/or throat. Some examples of a decongestant mayinclude pseudoephedrine and phenylephrine. A diuretic may include anagent for increasing the quantity of urine produced by the kidneys andpassed out of the body. Some examples of a diuretic may includehydrochlorothiazide, spironolactone, mannitol, and/or glucose. Anexpectorant may include an agent for stimulating the flow of saliva,loosening and thinning mucus in airways, and/or promoting a moreproductive cough as to eliminate phlegm from the respiratory tract. Anexample of an expectorant may include guaifenesin. A hormone may includemolecules produced naturally by the endocrine glands. Some examples of ahormone may include steroid hormones, amine-derived hormones, peptidehormones, and/or lipid and phospholipid-derived hormones. A hypoglycemicmay include an agent for lowering the level of glucose in the blood.Some examples of a hypoglycemic may include a sulfonylurea, ameglitinide, a biguanide, a thiazolidinedione, and/or aalpha-glucosidase inhibitor. An immunosuppressive may include an agentfor preventing or reducing the body's normal reaction to invasion bydisease and/or foreign tissues. Some examples of an immunosuppressivemay include a drug such as a corticosteroid, cyclosporine, rapamycin,which acts on immunophilins, and/or an antibody.

A laxative may include an agent for increasing the frequency and ease ofbowel movements. Some examples of a laxative may includemethylcellulose, docusate, mineral oil, and/or magnesium hydroxide. Amuscle relaxant may include an agent utilized for relieving musclespasms. Some examples of a muscle relaxant may include neuromuscularblocking drugs, carisoprodol, cyclobenzaprine, metaxalone, abenzodiazepine and/or a tranquilizer. A sedative may include a substancewhich depresses the central nervous system and may result in calmness,relaxation, reduction of anxiety, sleepiness, and/or slowed breathing.Some examples of a sedative may include zolpidem, and/or eszopiclone. Afemale sex hormone may include a hormone responsible for the developmentof female secondary sexual characteristics. Some examples of a femalesex hormone may include estrogen and progesterone. A mate sex hormonemay include a hormone responsible for the development of secondary malesexual characteristics. One example of a mate sex hormone may includetestosterone. Sex hormone-related agents may include agentsmetabolically related to sex hormones. Examples of sex hormone-relatedagents may include sterols, androgens (testosterone), progestogensestrogens (estradiols, estrone), follicle-stimulating hormone,luteinizing hormone, inhibin B, anti-Mullerian hormone thyroid-relatedhormones. A tranquilizer may include any drug having a calming and/orsedative effect. Some examples of a tranquilizer may include anantidepressant, a barbiturate, and/or a benzodiazepine. An appetitemodulator may include an agent used for regulating and/or adjustingappetite. Some examples of an appetite modulator may include recombinantPYY 3-36 and/or sibutramine. A vitamin may include chemicals essentialin relatively small quantities for good health. Some examples of avitamin may include Vitamin A, Vitamin C, Vitamin D, and/or Vitamin K.

In one instance, selector module 106 can select an analgesic and anantipsychotic for subsequent presentation, perhaps in response toaccepting a pain symptom and a hallucination symptom as the at least oneattribute. In some instances, selector module 106 may include a computerprocessor.

FIG. 18 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 18 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 1802. Further, operation 1802illustrates selecting at least one of an antiparalytic, an antimanic, anantineuralgic, an anti-dyskinesia agent, an antispasmodic, anantiadrenergic, an antimuscarinic, a neuromimetic agent, a neuromuscularagent, an antianxiety agent, an antipsychotic, an antidepressant, a moodstabilizer, a stimulant, an anxiolytic, a hypnotic, or a sleeping agent.For example, as shown in FIG. 1, selector module 106 may select at leastone of an antiparalytic, an antimanic, an antineuralgic, ananti-dyskinesia agent, an antispasmodic, an antiadrenergic, anantimuscarinic, a neuromimetic agent, a neuromuscular agent, anantianxiety drug, an antipsychotic, an antidepressant, a moodstabilizer, a stimulant, an anxiolytic, a hypnotic, and/or a sleepingagent such as a long-acting barbiturate. In one example, selector module106 selects an antianxiety drug and a sleeping agent. An antiparalyticmay include an agent used for preventing the loss of and/or recoveringmuscle function. One example of an antiparalytic may includemethylprednisolone. An antimanic may include an agent used for treatingand/or suppressing mania. Some examples may include lamotrigine and/orcarbamazepine. An antineuralgic may include an agent for relievingparoxysmal nerve pain. One example of an antineuralgic may includecarbamazepine. An anti-dyskinesia agent may include an agent used forreducing and/or preventing dyskinesia, including involuntary musclemovement. One example of an anti-dyskinesia agent may includemethylenedioxymethamphetamine. An antispasmodic may include a drug or anherb that suppresses smooth muscle contraction. Some examples of anantispasmodic may include dicyclomine and/or hyoscyamine. Anantiadrenergic may include a medication for inhibiting the functioningof the sympathetic nervous system. Some examples of an antiadrenergicmay include clonidine and/or mecamylamine. An antimuscarinic may includean agent for reducing the activity of the muscarinic acetylcholinereceptor. Some examples of an antimuscarinic may include atropine and/orhyoscine. A neuromimetic agent may include an agent that mimics theresponse of an effector organ to nerve impulses. A neuromuscular agentmay block neuromuscular transmission at the neuromuscular junction andcause paralysis of the affected skeletal muscles. Some examples of aneuromuscular agent may include atracurium and/or vecuronium. Anantianxiety drug may include a drug for suppressing anxiety and relaxingthe muscles. An antianxiety drug may include a sedative, a tranquilizer,an anxiolytic, such as a benzodiazepine, alprazolam and/or diazepam, anantidepressant, a short-acting barbiturate, and/or an herbal treatment,such as chamomile, kava extract, Kratom, and/or valerian. Anantipsychotic may include a group of drugs commonly used to treatpsychosis and may include phenothiazines, thioxanthenes, butyrophenones,risperidone, amisulpride, and/or other suitable drugs. An antidepressantmay include a psychiatric medication or other substance, such as anutrient or herb, used for alleviating depression or dysthymia. Someexamples of an antidepressant may include a selective serotonin reuptakeinhibitor, such as Prozac and/or Zoloft, and/or aserotonin-norepinephrine reuptake inhibitor, such as Cymbalta. A moodstabilizer may include a psychiatric medication used to treat mooddisorders characterized by intense and sustained mood shifts. Someexamples of a mood stabilizer may include lithium carbonate and/orlamotrigine. A stimulant may include substances that may temporarilyincrease alertness and awareness, such as caffeine, ephedrine, and/ornicotine. An anxiolytic may include a substance used for the treatmentof anxiety, such as a benzodiazepine and/or a barbiturate. A hypnoticmay include substances that induce steep, such as a barbiturate and/oran antihistamine (diphenhydramine). A sleeping agent may include anynumber of medications for helping a person sleep and/or stay asleep andmay include benzodiazepines, antidepressants, melatonin, and/orantihistamines as well as other suitable substances. In some instances,selector module 106 may include a computer processor.

FIG. 19 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 19 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 1902, an operation 1904, and/or anoperation 1906.

Operation 1902 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a behavior, asymptom, or a diagnosis. For example, as shown in FIG. 1, selectormodule 106 may select the at least one prescription medication at leastpartially based on at least one of a behavior, a symptom, or adiagnosis. In one instance, selector module 106 can select aprescription medication based on a diagnosis. A behavior may include themanner a person behaves toward other people and/or a certaincircumstance. A symptom may include a subjective indicator of a healthproblem reported by an individual, or a sign of a health problem noticedby another, perhaps a doctor. A symptom may be evidence of a disease, adisability, an impairment, and/or a condition. A diagnosis may includean identification of a disease, a disability, an impairment, and/or acondition. In some instances, selector module 106 may include a computerprocessor.

Operation 1904 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a susceptibilityto a drug side effect or a drug interaction. For example, as shown inFIG. 1, selector module 106 may select the at least one prescriptionmedication at least partially based on at least one of a susceptibilityto a drug side effect or a drug interaction. In one instance, selectormodule 106 can select a prescription medication based on asusceptibility to a drug side effect including an allergy. Asusceptibility to a drug side effect may include a probability a certainperson may be vulnerable to a side effect associated with a specificdrug and/or medication. A susceptibility to a drug side effect mayinclude predisposition to a particular drug side effect or class of drugside effects, such as upset stomach associated with aspirinformulations. A drug reaction may include a possible response a personmay exhibit resulting from at least one drug and/or medicationadministered to the person. A drug reaction may include an allergyand/or a drug and/or medication interaction with a separate drug and/ormedication. In some instances, selector module 106 may include acomputer processor.

Operation 1906 illustrates selecting a prescription medication and atleast one alternative medicine treatment as the at least oneprescription medication. For example, as shown in FIG. 1, selectormodule 106 may select a prescription medication and at least onealternative medicine treatment as the at least one prescriptionmedication. In one instance, selector module 106 can select aprescription medication and at least one alternative medicine treatmentas the at least one prescription medication. A prescription medicationmay include a medication, drug, and/or treatment available only withwritten instructions from a doctor, dentist, and/or other licensedprofessional. An alternative medicine treatment may include medicaland/or nutraceutical treatments and/or practices utilized instead ofstandard medical treatments. Some examples of alternative medicinetreatments may include chiropractic, herbal medicine, acupuncture,homeopathy, naturopathy, and/or spiritual devotions. In some instances,selector module 106 may include a computer processor.

FIG. 20 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 20 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2002, and/or an operation 2004.

Operation 2002 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a medicationhistory of the at least one individual or an artificial sensoryexperience history of the at least one individual. For example, as shownin FIG. 1, selector module 106 may select the at least one prescriptionmedication at least partially based on at least one of a medicationhistory of the at least one individual or an artificial sensoryexperience history of the at least one individual. In one example,selector module 106 can select a prescription medication based on amedication history of an individual named Jennifer Harris or ananonymous individual. A medication history may include any record ofadministered medications and/or drugs that may exist for an individual.An artificial sensory experience history may include any record of anartificial sensory experience associated with an individual. In someinstances, selector module 106 may include a computer processor.

Operation 2004 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a genetic or anepigenetic profile. For example, as shown in FIG. 1, selector module 106may select the at least one prescription medication at least partiallybased on at least one of a genetic or an epigenetic profile. In oneinstance, selector module 106 can select a prescription medication basedon a genetic profile. A genetic profile may include hereditaryinformation encoded in the genetic sequence of an individual. Anepigenetic profile may include information regarding chromatin and/orDNA modifications that are stable over rounds of cell division but donot involve changes in the underlying DNA sequence of the organism, suchas histone acetylation and/or DNA methylation. Other epigeneticinformation may be found in higher-order chromatin structure. In someinstances, selector module 106 may include a computer processor.

FIG. 21 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 21 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2102, and/or an operation 2104.

Operation 2102 illustrates selecting at least one virtual experience asthe at least one artificial sensory experience. For example, as shown inFIG. 1, selector module 106 may select at least one virtual experienceas the at least one artificial sensory experience. In one example,selector module 106 can select a virtual experience as the artificialsensory experience. A virtual experience may include an experience witha computer-simulated environment. Such a virtual experience may beinteractive or non-interactive. Some examples of a virtual experiencemay include an experience with a virtual world, a simulated reality, acomputer game, and/or a virtual tour, and may involve input devices suchas a keyboard, a mouse, an accelerometer-containing input device, and/ora wired glove. A virtual experience may also involve a visual and/orauditory monitoring device such as a video monitor, goggles,loudspeakers, or the like. Examples of a virtual experience includesecond life, snow world, or the like. In some instances, selector module106 may include a computer processor.

Operation 2104 illustrates selecting at least one of a virtual world, asocial networking website, an online game, an online educationalexperience, a networked game, or a single-player game. For example, asshown in FIG. 1, selector module 106 may select at least one of avirtual world, a social networking website, an online game, an onlineeducational experience, a networked game, or a single-player game. Inone instance, selector module 106 can select a virtual world. A virtualworld may include a computer-based simulated environment intended forits users to inhabit and interact via avatars, such as second life. Asocial networking website may include a website for observing and/orinteracting with one or more personal and/or professional relationshipsbetween individuals. Some examples of a social networking website mayinclude MySpace, GeoCities, Facebook, and/or LinkedIn. In one instance,selector module 106 may select Facebook as the social networking websiteand may include directions to Facebook to implement a color schemeincluding bright colors, such as yellow and light blue, for preventingthe onset of depression in a depression prone viewer. An online game mayinclude a game played over a network, such as hardwired terminals, awireless network, a modem network, a video console, and/or the internet.Some online games may include virtual worlds and/or virtual communities.Examples of online games may include World of Warcraft (WoW), FinalFantasy XI, Lineage II, Guild Wars, and/or RuneScape. An onlineeducational experience may include a tutorial, a lesson, and/or anonline class. Some examples of an online educational experience mayinclude a HTML tutorial, an online piano Lesson, and/or an online degreeprogram from the University of Phoenix. A networked game may include anygame played by more than one player and may be played on a computer. Anexample of a networked game may include World of Warcraft (WoW). Asingle-player game may include any game that can be played by one playerand that may or may not be played on a computer. Examples of asingle-player game includes solitaire, puzzle games such as Tetris, Callof Duty, and Guitar Hero. In some instances, selector module 106 mayinclude a computer processor.

FIG. 22 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 22 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2202, and/or an operation 2204.

Operation 2202 illustrates selecting at least one real-world sensorystimulus as the at least one artificial sensory experience. For example,as shown in FIG. 1, selector module 106 may select at least onereal-world sensory stimulus as the at least one artificial sensoryexperience. In one instance, selector module 106 can select a real-worldsensory stimulus including an aroma as an artificial sensory experience.Some examples of a real-world sensory stimulus may include aromas and/orsmells, sounds, sights, touch, pressure, temperature and/or heat, and/orvibration. In some instances, selector module 106 may include a computerprocessor. Further, operation 2204 illustrates selecting at least one ofa smell, a taste, a sound, a physical contact, or a sight as the atleast one real-world sensory stimulus. For example, as shown in FIG. 1,selector module 106 may select at least one of a smell, a taste, asound, a physical contact, or a sight as the at least one real-worldsensory stimulus. In one example, selector module 106 selects a smelland a taste as a real-world sensory stimulus. A smell may include anyproperty detected by the nose and/or olfactory system. A taste mayinclude any flavor and/or property detected by the tongue and/or tastebuds. A sound may include any sound wave that may be detected by theeardrum. A physical contact may include anything related to touch, feel,and/or detection by the skin and/or body, and/or physical activityincluding exercise. In one instance, selector module 106 may select aphysical contact including physical exercise associated withparticipating in playing a tennis game on a Nintendo Wii video gameconsole, for example. A sight may include any image, and/or lightdetected by the eyes. In some instances, selector module 106 may includea computer processor.

FIG. 23 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 23 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2302, an operation 2304, and/or anoperation 2306.

Operation 2302 illustrates selecting the at least one artificial sensoryexperience at least partially based on at least one of a behavior, asymptom, or a diagnosis. For example, as shown in FIG. 1, selectormodule 106 may select the at least one artificial sensory experience atleast partially based on at least one of a behavior, a symptom, or adiagnosis. In one example, selector module 106 can select an artificialsensory experience based on behavior entered by a user 118 via a userinterface 116. A behavior may include the manner in which a personand/or thing acts and/or reacts. A symptom may include a manifestation,sign, and/or an indication of the presence of a disease and/or someother disorder and/or abnormality. A diagnosis may include identifying adisease and/or condition by its signs and/or symptoms. For example,selector module 106 and/or system 100 may select an immersive virtualreality experience as the at least one artificial sensory experience atleast partially based on a pain symptom and/or a third-degree burndiagnosis. In some instances, selector module 106 may include a computerprocessor.

Operation 2304 illustrates selecting the at least one artificial sensoryexperience at least partially based on at least one demographiccharacteristic of the at least one individual. For example, as shown inFIG. 1, selector module 106 may select the at least one artificialsensory experience at least partially based on at least one demographiccharacteristic of the at least one individual. In one example, selectormodule 106 can select an artificial sensory experience based on ademographic characteristic the at least one individual. A demographiccharacteristic may include a socioeconomic, age, gender, and/or othersimilar factor defining a certain population. For example, selectormodule 106 and/or system 100 may select a virtual reality experiencesuch as a Sesame Street or Disney-themed experience as the at least oneartificial sensory experience at least partially based on an indicationthat the individual is aged 6-10 years old. In some instances, selectormodule 106 may include a computer processor.

Further, operation 2306 illustrates selecting the at least oneartificial sensory experience at least partially based on at least oneof geographic location, family status, age, gender, weight, ethnicity,body mass index, household size, or income of the at least oneindividual. For example, as shown in FIG. 1, selector module 106 mayselect the at least one artificial sensory experience at least partiallybased on at least one of geographic location, family status, age,gender, weight, ethnicity, body mass index, household size, or income ofthe at least one individual. In one example, selector module 106 canselect the artificial sensory experience based on an age and a weightassociated with the at least one individual. A geographic location mayinclude a location where an individual currently resides, has resided inthe past, and/or has visited. A family status may include maritalstatus, status and/or presence of children, and/or the status and/orhealth of extended family. In some instances, selector module 106 mayinclude a computer processor.

FIG. 24 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 24 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2402, and/or an operation 2404.

Operation 2402 illustrates selecting the at least one artificial sensoryexperience at least partially based on at least one of a medicationhistory or an artificial sensory experience history of the at least oneindividual. For example, as shown in FIG. 1, selector module 106 mayselect the at least one artificial sensory experience at least partiallybased on at least one of a medication history or an artificial sensoryexperience history of the at least one individual. In one instance,selector module 106 can select an artificial sensory experience based onan artificial sensory experience history of the at least one individual.An artificial sensory experience history may include any record of atleast one administered artificial sensory experience history. Forexample, system 100 and/or selector module 106 may select a modifiedfacebook webpage having a cheerful color scheme at least partly based ona facebook usage history for an individual with signs of depression. Insome instances, selector module 106 may include a computer processor.

Operation 2404 illustrates selecting a preferred artificial sensoryexperience and at least one alternative artificial sensory experience.For example, as shown in FIG. 1, selector module 106 may select apreferred artificial sensory experience and at least one alternativeartificial sensory experience. In one example, selector module 106 canselect a preferred artificial sensory experience and at least onealternative artificial sensory experience. A preferred artificialsensory experience may include a more desirable artificial sensoryexperience due to a lack of and/or a reduced level of side effects,reduced impact upon the individual, and/or increased compatibility withanother medications and/or treatment. An alternative artificial sensoryexperience may include any artificial sensory experience in addition tothe preferred artificial sensory experience and may be less desirablethan the preferred artificial sensory experience due to side effectsand/or increased impact upon the individual. In some instances, selectormodule 106 may include a computer processor.

FIG. 25 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 25 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2502, an operation 2504, and/or anoperation 2506.

Operation 2502 illustrates selecting at least one artificial sensoryexperience and at least one prescription medication at least partiallybased on a treatment algorithm. For example, as shown in FIG. 1,selector module 106 may select at least one artificial sensoryexperience and at least one prescription medication at least partiallybased on a treatment algorithm. In one instance, selector module 106 canselect an artificial sensory experience and a prescription medicationbased on a computer software treatment algorithm. A treatment algorithmmay include any computation, formula, statistical survey, and/or look-uptable for determining and/or selecting a suitable artificial sensoryexperience and prescription medication combination. Some examples mayinclude a computer software algorithm, a calculator, a flowchart, and/ora decision tree. For example, system 100 and/or selector module 106 may,based on an accepted pain symptom of an individual, access a lookupchart that matches the pain symptom with a pain medication, such asnaproxen, and a virtual experience, such as World of Warcraft. Such acombination therapy may be particularly effective in ameliorating thepain symptom in the individual. In some instances, selector module 106may include a computer processor.

Further, operation 2504 illustrates selecting at least one prescriptionmedication at least partially based on at least one of a drug allergyassociated with the at least one individual or a drug interactionassociated with the at least one prescription medication. For example,as shown in FIG. 1, selector module 106 may select at least oneprescription medication at least partially based on at least one of adrug allergy associated with the at least one individual or a druginteraction associated with the at least one prescription medication. Inone example, selector module 106 can select a prescription medicationbased on a drug allergy associated with the at least one individual. Adrug allergy may include any allergy to a drug and/or drug intolerance.Some examples of a drug allergy may include penicillin allergies,codeine allergies, and/or allergies to a dye in a drug. A druginteraction may include an undesirable and/or unwanted reaction betweentwo or more drugs and/or medications. For example, the system 100 and/orselector module 106 can select a prescription medication other thanthose that might cause a side effect in an individual, perhaps becauseof a known predisposition to the side effect (e.g., an allergy) orbecause of a known drug-drug interaction relevant to the individualbased on the individual's medication regimen. In this way, risk of sideeffects can be lessened. In some instances, selector module 106 mayinclude a computer processor.

Operation 2506 illustrates selecting at least one opioid analgesic andat least one virtual world experience to address at least one painattribute of at least one individual. For example, as shown in FIG. 1,selector module 106 may select from a prescription medication databaseat least one opioid analgesic and at least one virtual world experienceto address at least one pain attribute of at least one individual. Inone example, selector module 106 can select an opioid analgesicincluding morphine and a virtual world experience including an onlinegame to address a pain attribute of at least one individual named MaryAndersen. In some instances, selector module 106 may include a computerprocessor.

FIG. 26 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 26 illustrates example embodiments whereoperation 240 may include at least one additional operation. Additionaloperations may include an operation 2602, an operation 2604, and/or anoperation 2606.

Operation 2602 illustrates presenting an indication of a preferredcombination including at least one prescription medication and at leastone artificial sensory experience and at least one alternativecombination including at least one alternative prescription medicationand at least one alternative artificial sensory experience. For example,as shown in FIG. 1, presenter module 108 may present an indication of apreferred combination including at least one prescription medication andat least one artificial sensory experience and at least one alternativecombination including at least one alternative prescription medicationand at least one alternative artificial sensory experience. In oneinstance, presenter module 108 can present an indication of a preferredcombination to an individual 134 including a prescription medication andan artificial sensory experience along with an alternative combinationincluding an alternative prescription medication and an alternativeartificial sensory experience. Individual 134 may include a singleindividual, multiple individuals, and/or an entity. A preferredcombination may include a more desirable combination due to a lack ofand/or a reduced number of and/or level of side effects, reduced impactupon the administered individual, and/or increased compatibility withanother medications and/or treatment. An alternative combination mayinclude any combination in addition to the preferred combination and maybe ostensibly less desirable than the preferred artificial sensoryexperience because of a potential side effect and/or impact upon theadministered individual. Presentation of alternative combinations mayprovide benefits to the individual in terms of accessibility,affordability, and/or personal preference of medication and/orartificial sensory experience. In some instances, presenter module 108may include a computer processor.

Operation 2604 illustrates presenting an indication of the at least oneprescription medication and the at least one artificial sensoryexperience to at least one output device. For example, as shown in FIG.1, presenter module 108 may present an indication of the at least oneprescription medication and the at least one artificial sensoryexperience to at least one output device. In one example, presentermodule 108 can present an indication of a prescription medication and anartificial sensory experience to an output device 130 including aprinter at a health clinic. An output device may include any hardwaredevice configured for receiving computer output. Some examples of anoutput device may include a printer, a monitor, a mobile phone, aspeaker, and/or a visual display unit. The output device may be used byindividual 134. In some instances, presenter module 108 may include acomputer processor.

Further, operation 2606 illustrates presenting an indication of at leastone of the at least one prescription medication or the at least oneartificial sensory experience to at least one user interface. Forexample, as shown in FIG. 1, presenter module 108 may present anindication of at least one of the at least one prescription medicationor the at least one artificial sensory experience to at least one userinterface. In one instance, presenter module 108 can present anindication of a prescription medication and an artificial sensoryexperience to a user interface. A user interface may include means bywhich an individual may interact with a system. Some examples of a userinterface may include a touchscreen, a graphical user interface, atactile interface, and/or a live user interface. In some instances,presenter module 108 may include a computer processor.

FIG. 27 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 27 illustrates example embodiments whereoperation 240 may include at least one additional operation. Additionaloperations may include an operation 2702. Further, operation 2702illustrates presenting an indication of at least one of the at least oneprescription medication or the at least one artificial sensoryexperience to at least one mobile device. For example, as shown in FIG.1, presenter module 108 may present an indication of at least one of theat least one prescription medication or the at least one artificialsensory experience to at least one mobile device. In one instance,presenter module 108 can present an indication of a prescriptionmedication to a mobile device 132. A mobile device may include aportable computing device and may have wireless connection capability.Some examples of a mobile device may include a laptop or notebookcomputer, a personal digital assistant (PDA), an ipod, a smartphone, anEnterprise digital assistant (EDA), and/or a pager. In some instances,presenter module 108 may include a computer processor.

FIG. 28 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 28 illustrates example embodiments whereoperation 240 may include at least one additional operation. Additionaloperations may include an operation 2802, and/or an operation 2804.

Operation 2802 illustrates presenting to a health care provider anindication of at least one of the at least one prescription medicationor the at least one artificial sensory experience at least partly basedon the selecting at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. For example, as shown in FIG. 1, presentermodule 108 may present to a health care provider an indication of atleast one of the at least one prescription medication or the at leastone artificial sensory experience at least partly based on the selectingat least one prescription medication and at least one artificial sensoryexperience to address an attribute of an individual. In one example,presenter module 108 can present to a health care provider 128 anindication of a prescription medication based on the selecting at leastone prescription medication and at least one artificial sensoryexperience to address the at least one attribute 120 of at least oneindividual. A health care provider may include a pharmacy, apharmaceutical company, a medical device company, a researchinstitution, a computer software and/or computer hardware company, awebsite, a nurse and/or a physician. In some instances, presenter module108 may include a computer processor.

Operation 2804 illustrates presenting an indication of the at least oneprescription medication or the at least one artificial sensoryexperience at a staggered time. For example, as shown in FIG. 1,presenter module 108 may present an indication of at least one of the atleast one prescription medication or the at least one artificial sensoryexperience at a staggered time. In one example, presenter module 108 canpresent an indication of a series of prescription medications and anartificial sensory experience at staggered times. A staggered time mayinclude presenting an indication of the at least one drug and/orartificial sensory experience at overlapping times and/or at differenttimes, including alternating times. For example, at least one drug andan artificial sensory experience may be administered at an initial timeand the same or a different drug may be administered when thefirst-administered at least one drug is at its peak effect. In anotherexample, at least one drug and an artificial sensory experience may beadministered at an initial time and the same or a different drug may beadministered when the first administered at least one drug is at itslowest effect. In another example, an artificial sensory experience maybe administered at an initial time and at least one prescriptionmedication at a later time. The at least one artificial sensoryexperience and/or the at least one prescription medication may beadministered at any number of times either concurrently, partiallyconcurrently, or not concurrently. In some instances, presenter module108 may include a computer processor.

FIG. 29 illustrates an operational flow 2900 representing exampleoperations related to querying at least one database at least partlybased on at least one attribute of an individual, selecting from the atleast one database at least one prescription medication to address theat least one attribute of at least one individual, and/or implementingat least one artificial sensory experience to address the at least oneattribute of at least one individual in response to a selected at leastone prescription medication. In FIG. 29, discussion and explanation maybe provided with respect to the above-described examples of FIG. 1,and/or with respect to other examples and contexts. However, it shouldbe understood that the operational flows may be executed in a number ofother environments and contexts, and/or in modified versions of FIG. 1.Also, although the various operational flows are presented in thesequence(s) illustrated, it should be understood that the variousoperations may be performed in other orders than those which areillustrated, or may be performed concurrently.

After a start operation, the operational flow 2900 moves to an operation2910. Operation 2910 depicts querying at least one database at leastpartly based on at least one attribute of an individual. For example, asshown in FIG. 1, querier module 104 may search at least one database atleast partly based on at least one attribute of an individual. In oneinstance, querier module 104 may search medication database 124 andartificial sensory experience database 126 based on an attribute 120including an indication of hypertension associated with an individualnamed John Smith. In some instances, querier module 104 may include acomputer processor.

Then, operation 2920 depicts selecting from the at least one database atleast one prescription medication to address the at least one attributeof at least one individual. For example, as shown in FIG. 1, selectormodule 106 may select from the at least one database at least oneprescription medication to address the at least one attribute of atleast one individual. In one example and continuing with the previousexample, selector module 106 may select from medication database 124 andartificial sensory experience database 126 a prescription medicine foraddressing the attribute 120 including an indication of hypertensionassociated with an individual named John Smith. In some instances,selector module 106 may include a computer processor.

Then, operation 2930 depicts implementing at least one artificialsensory experience to address the at least one attribute of at least oneindividual in response to a selected at least one prescriptionmedication. For example, as shown in FIG. 1, implementer module 138 mayimplement at least one artificial sensory experience to address the atleast one attribute of at least one individual in response to a selectedat least one prescription medication. In one instance and continuingwith the previous example, implementer module 106 may implement anartificial sensory experience including a virtual world for addressingthe attribute 120 including an indication of hypertension associatedwith an individual named John Smith in response to a selectedprescription medication from a medication database 124. In someinstances, selector module 106 may include a computer processor.

FIG. 30 illustrates a partial view of an example computer programproduct 3000 that includes a computer program 3004 for executing acomputer process on a computing device. An embodiment of the examplecomputer program product 3000 is provided using a signal-bearing medium3002, and may include one or more instructions for accepting at leastone attribute of at least one individual; one or more instructions forquerying at least one database at least partly based on the at least oneattribute; one or more instructions for selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual; and one or more instructions for presenting anindication of the at least one prescription medication and the at leastone artificial sensory experience at least partly based on the selectingfrom the at least one database at least one prescription medication andat least one artificial sensory experience to address the at least oneattribute of at least one individual. The one or more instructions maybe, for example, computer executable and/or logic-implementedinstructions. In one implementation, the signal-bearing medium 3002 mayinclude a computer-readable medium 3006. In one implementation, thesignal bearing medium 3002 may include a recordable medium 3008. In oneimplementation, the signal bearing medium 3002 may include acommunications medium 3010.

FIG. 31 illustrates an example system 3100 in which embodiments may beimplemented. The system 3100 includes a computing system environment.The system 3100 also illustrates the user 118 using a device 3104, whichis optionally shown as being in communication with a computing device3102 by way of an optional coupling 3106. The optional coupling 3106 mayrepresent a local, wide-area, or peer-to-peer network, or may representa bus that is internal to a computing device (e.g., in exampleembodiments in which the computing device 3102 is contained in whole orin part within the device 3104). A storage medium 3108 may be anycomputer storage media.

The computing device 3102 includes computer-executable instructions 3110that when executed on the computing device 3102 cause the computingdevice 3102 to accept at least one attribute of at least one individual;query at least one database at least partly based on the at least oneattribute; select from the at least one database at least oneprescription medication and at least one artificial sensory experienceto address the at least one attribute of at least one individual; andpresent an indication of the at least one prescription medication andthe at least one artificial sensory experience at least partly based onthe selecting from the at least one database at least one prescriptionmedication and at least one artificial sensory experience to address theat least one attribute of at least one individual. As referenced aboveand as shown in FIG. 31, in some examples, the computing device 3102 mayoptionally be contained in whole or in part within the device 3104.

In FIG. 31, then, the system 3100 includes at least one computing device(e.g., 3102 and/or 3104). The computer-executable instructions 3110 maybe executed on one or more of the at least one computing device. Forexample, the computing device 3102 may implement the computer-executableinstructions 3110 and output a result to (and/or receive data from) thecomputing device 3104. Since the computing device 3102 may be wholly orpartially contained within the computing device 3104, the device 3104also may be said to execute some or all of the computer-executableinstructions 3110, in order to be caused to perform or implement, forexample, various ones of the techniques described herein, or othertechniques.

The device 3104 may include, for example, a portable computing device,workstation, or desktop computing device. In another example embodiment,the computing device 3102 is operable to communicate with the device3104 associated with the user 118 to receive information about the inputfrom the user 118 for performing data access and data processing andpresenting an output of the user-health test function at least partlybased on the user data.

Although a user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that a user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents). In addition, a user 118, asset forth herein, although shown as a single entity may in fact becomposed of two or more entities. Those skilled in the art willappreciate that, in general, the same may be said of “sender” and/orother entity-oriented terms as such terms are used herein.

FIG. 32 illustrates system 3200 for measuring at least one effect of acombined bioactive agent and artificial sensory experience on anindividual, modifying at least one of the bioactive agent or theartificial sensory experience at least partially based on the at leastone effect, modifying an artificial sensory experience to enhance theefficacy of the bioactive agent, and/or presenting an indication of amodified combined bioactive agent and artificial sensory experience atleast partially based on a modified at least one bioactive agent orartificial sensory experience. The system 3200 may include measurermodule 3402, modifier module 3418, indication presenter module 3460,monitoring unit 3202, and/or administration unit 3222. Administrationunit 3222 may include physical intervention effector module 3224 and/orartificial sensory experience effector module 3226. Monitoring unit 3202may include drug sensing unit 3204, physiologic activity monitor 3206,brain activity measurement unit 3208, behavior monitor 3210,instrumentation monitor 3212, compliance reporting unit 3214, voiceresponse module 3216, hearing test module 3218, and/or scale 3220.Additionally, system 3200 may include mobile device 132.

FIG. 33 illustrates system 3200 for measuring at least one effect of acombined bioactive agent and artificial sensory experience on anindividual, modifying at least one of the bioactive agent or theartificial sensory experience at least partially based on the at leastone effect, modifying an artificial sensory experience to enhance theefficacy of the bioactive agent, and/or presenting an indication of amodified combined bioactive agent and artificial sensory experience atleast partially based on a modified at least one bioactive agent orartificial sensory experience. The system 3200 may include measurermodule 3402, modifier module 3418, acceptor module 102, monitoring unit3202, indication presenter module 3460 and/or administration unit 3222.Accepter module 102 may receive information and/or data from user 118,database 122, and/or health care provider 136. Database 122 may includemedication database 124 and/or artificial sensory experience database126. Monitoring unit 3202 may monitor individual 134, may becommunicatively coupled to modifier module 3418, and may include drugsensing unit 3204, physiologic activity monitor 3206, brain activitymeasurement unit 3208, behavior monitor 3210, instrumentation monitor3212, compliance reporting unit 3214, voice response module 3216,hearing test module 3218, and/or scale 3220. Administration unit 3222may be communicatively coupled to measurer module 3402 and may includephysical intervention effector module 3224 and/or artificial sensoryexperience effector module 3226. Additionally, mobile device 132 maycommunicate with acceptor module 102, assigner module 3334, monitoringunit 3202, and/or administration unit 3222.

FIGS. 34 and 35 further illustrate system 3200 including measurer module3402, modifier module 3418, and/or indication presenter module 3364.Measurer module 3402 may include data comparer module 3404, laboratorytest utilizer module 3406, self assessment measurer module 3408,computerized assessment measurer module 3410, and/or expected behaviormeasurer module 3414. Computerized assessment measurer module 3410 mayinclude virtual experience score measurer module 3412. Expected behaviormeasurer module 3414 may include behavior data comparer module 3416.Indication presenter module 3364 may include output device presentermodule 3462 and/or third party presenter module 3468. Output devicepresenter module 3462 may include user interface presenter module 3464and/or mobile device presenter module 3466. Third party presenter module3468 may include health care provider presenter module 3470 and/orselective presenter module 3472.

As further illustrated in FIG. 35, system 3200 may include modifiermodule 3418. Modifier module 3418 may include access modifier module3420, visual object modifier module 3426, sound alterer module 3432,dosage modifier module 3440, bioactive agent combination modifier module3442, bioactive agent delivery modifier module 3444, efficacy enhancingmodifier module 3446, side effect reduction modifier module 3448,visual/audio content adder module 3450, deleter module 3452, contentadder module 3454, and/or sensate experience modifier module 3456.Access modifier module 3420 may include access restrictor module 3422and/or access granter module 3424. Visual object modifier module 3426may include color scheme modifier module 3428 and/or text modifiermodule 3430. Sound alterer module 3432 may include music alterer module3434, ambient noise alterer module 3436, and/or voice alterer module3438. Sensate experience modifier module 3456 may include stimulusmodifier module 3458.

System 3200 generally represents instrumentality for measuring at leastone effect of a combined bioactive agent and artificial sensoryexperience on an individual, modifying at least one of the bioactiveagent or the artificial sensory experience at least partially based onthe at least one effect, modifying an artificial sensory experience toenhance the efficacy of the bioactive agent, and/or presenting anindication of a modified combined bioactive agent and artificial sensoryexperience at least partially based on a modified at least one bioactiveagent or artificial sensory experience. The operations of measuring atleast one effect of a combined bioactive agent and artificial sensoryexperience on an individual, modifying at least one of the bioactiveagent or the artificial sensory experience at least partially based onthe at least one effect, modifying an artificial sensory experience toenhance the efficacy of the bioactive agent, and/or presenting anindication of a modified combined bioactive agent and artificial sensoryexperience at least partially based on a modified at least one bioactiveagent or artificial sensory experience may be accomplishedelectronically, such as with a set of interconnected electricalcomponents, an integrated circuit, and/or a computer processor.

FIG. 36 illustrates an operational flow 3600 representing exampleoperations related to measuring at least one effect of a combinedbioactive agent and artificial sensory experience on an individual andmodifying at least one of the bioactive agent or the artificial sensoryexperience at least partially based on the at least one effect. In FIG.36 and in following figures that include various examples of operationalflows, discussion and explanation may be provided with respect to theabove-described examples of FIGS. 32 through 35, and/or with respect toother examples and contexts. However, it should be understood that theoperational flows may be executed in a number of other environments andcontexts, and/or in modified versions of FIGS. 32 through 35. Also,although the various operational flows are presented in the sequence(s)illustrated, it should be understood that the various operations may beperformed in other orders than those which are illustrated, or may beperformed concurrently.

After a start operation, the operational flow 3600 moves to operation3610. Operation 3610 depicts measuring at least one effect of a combinedbioactive agent and artificial sensory experience on an individual. Forexample, as shown in FIGS. 32 through 35, measurer module 3402 maymeasure an effect of a combined bioactive agent and artificial sensoryexperience on an individual. Some examples of measuring an effect mayinclude requesting and/or accepting one or more laboratory test results,for example a blood test; measuring one or more physiologic effects,such as heart rate; and/or measuring brain activity and/or function.Additional examples of measuring an effect may include using medicalimaging, such as magnetic resonance imaging and/or computed tomography.An effect may include a side effect and/or a desired effect. In someinstances, measurer module 3402 may include a computer processor and/ora medical device.

Then, operation 3620 depicts modifying at least one of the bioactiveagent or the artificial sensory experience at least partially based onthe at least one effect. For example, as shown in FIGS. 32 through 35,the modifier module 3418 may modify a bioactive agent and/or anartificial sensory experience at least partially based on an effect ofthe combined bioactive agent and artificial sensory experience. In oneinstance, modifier module 3418 may modify a virtual world in response toa measured effect of the bioactive agent. Some examples of a bioactiveagent may include a prescription medication, nutraceutical, and/ordietary supplement. Some examples of modifying a bioactive agent mayinclude changing a bioactive agent dosage, modifying a bioactive agentadministration method, adding a supplemental bioactive agent; and/orchanging the bioactive agent to another bioactive agent. Some examplesof an artificial sensory experience may include a virtual experience,such as an online game or a social networking site, and/or a real-worldsensory stimulus, such as a smell and/or a sight. Examples of modifyingan artificial sensory experience may include changing a computer gameand/or changing a computer display background content and/or emissionsetting. One example of administering an artificial sensory experiencemay include a game utilizing a neuroheadset having sensors for detectingmental state based on, for example, electrical signals and/or blood flowin the brain. See, for example, headsets manufactured by Emotiv Systems,Inc. In some instances, modifier module 3418 may include a computerprocessor.

FIG. 37 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 37 illustrates example embodiments whereoperation 3610 may include at least one additional operation. Additionaloperations may include operation 3702, operation 3704, and/or operation3706.

Operation 3702 illustrates comparing empirical data with a currenteffect measurement. For example, as shown in FIGS. 32 through 35, datacomparer module 3404 may compare empirical data with a current effectmeasurement. In one instance, data comparer module 3404 may compare aset of previous experimental data with a current effect measurement,such as a pulse measurement. Empirical data may include data obtainedfrom experimentation and/or observation. Some examples of empirical datamay include results from a clinical trial and/or data collection frommedical records, e.g., data obtained through data mining. Furtherdiscussion regarding data mining may be found in Oren et al., U.S. Pat.No. 6,807,492, which is incorporated herein by reference. Additionally,empirical data may be obtained through a lab information system (LIS),such as the system discussed in Birkner et al., U.S. Pat. No. 6,826,498,which is incorporated herein by reference. In some instances, datacomparer module 3404 may include a computer processor.

Operation 3704 illustrates measuring the at least one effect at leastone of during or after the individual experiences the combined bioactiveagent and artificial sensory experience. For example, as shown in FIGS.32 through 35, measurer module 3402 may measure an effect during orafter an individual experiences the combined bioactive agent andartificial sensory experience. The effect may be measured using, forexample, a medical device, a laboratory testing protocol, and/or aphysician's observation. The effect may be measured during and/or afteradministration of an artificial sensory experience and bioactive agentcombination for comparing one or more effects of the combination atdifferent times and/or compared to one or more pre-administrationmeasurements. In one embodiment, measurer module 3402 may measure anindividual's blood pressure during and after administration of acombination artificial sensory experience and bioactive agent andcompare the different measurements to determine the extent of thecombination effect on the individual. In some instances, measurer module3402 may include a computer processor, a medical device, and/or acombination of a computer processor and medical device.

Further, operation 3706 illustrates utilizing at least one laboratorytest to measure the at least one effect. For example, as shown in FIGS.32 through 35, laboratory test utilizer module 3406 may utilize alaboratory test to measure the effect. A laboratory test may include,for example, a design of experiments test (e.g., a test where one ormore parameters is changed to observe the effect the changes have on oneor more response variables), a blood test, a DNA analysis test, atoxicology test, a urinalysis, and/or a histopathological test. Suchtests may serve to determine the effect of a combination bioactive agentand artificial sensory experience on an individual. In some instances,laboratory test utilizer module 3406 may include a computer processorand/or medical instrumentation.

FIG. 38 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 38 illustrates example embodiments whereoperation 3610 may include at least one additional operation. Additionaloperations may include operation 3802, operation 3804, and/or operation3806.

Operation 3802 illustrates measuring the at least one effect with a selfassessment. For example, as shown in FIGS. 32 through 35, selfassessment measurer module 3408 may measure an effect with a selfassessment. A self assessment may include a judgment by the individualregarding the individual's own condition. In one embodiment, theindividual may input into self assessment measurer module 3408 anindication of a level of pain being experienced. The individual mayinput an indication of pain using a pain scale, such as a Faces PainScale (FPS) and/or a Pediatric Pain Questionnaire (PPQ). In someinstances, self assessment measurer module 3408 may include a computerprocessor and/or an input device, such as a touchscreen display.

Operation 3804 illustrates measuring the at least one effect with acomputerized assessment. For example, as shown in FIGS. 32 through 35,computerized assessment measurer module 3410 may measure the at leastone effect with a computerized assessment. A computerized assessment mayinclude, for example, inputting and/or receiving an indication of atleast one effect and computationally determining the existence and/orextent of an effect. One example of a cognitive assessment tool mayinclude inputting patient information, recommending a battery of tests,administering the tests, and/or processing the test results. Furtherdiscussion regarding a cognitive assessment tool may be found in Simonet al., U.S. Pat. No. 7,294,107, which is incorporated herein byreference. In some instances, computerized assessment measurer module3410 may include a computer processor, an input device, and/or medicalinstrumentation. Further, operation 3806 illustrates measuring the atleast one effect with a virtual experience score. For example, as shownin FIGS. 32 through 35, virtual experience score measurer module 3412may measure an effect with a virtual experience score. In oneembodiment, virtual experience score measurer module 3412 may measure aneffect of a combination antianxiety medication combined with a virtualexperience, such as a World of Warcraft game. In this embodiment, a lowscore may indicate efficacy of the antianxiety medicationadministration. In some instances, virtual experience score measurermodule 3412 may include a computer processor.

FIG. 39 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 39 illustrates example embodiments where theoperation 3610 may include at least one additional operation. Additionaloperations may include operation 3902, and/or operation 3904. Operation3902 illustrates measuring an expected behavior.

For example, as shown in FIGS. 32 through 35, expected behavior measurermodule 3414 may measure an expected behavior. An expected behavior mayinclude a behavior that is expected and/or predicted to occur. Oneexample of measuring an expected behavior may include measuring anindividual's pulse during administration and/or bioavailability of anantianxiety medication to an individual and while the individual isengaged with an artificial sensory experience. In this example, anexpected behavior may include a decrease in pulse proximate toadministration of the medication and engagement with the artificialsensory experience. Another example of measuring an expected behaviormay include measuring an individual's pain while she is beingadministered an opioid and experiencing an artificial sensory experienceas a means for distraction. In this example, an expected behavior may bea reduction in pain due to the effects of the opioid and the artificialsensory experience. In some instances, expected behavior measurer module3414 may include a computer processor and/or medical instrumentation.

Further, operation 3904 illustrates comparing current measured behaviordata with expected behavior data. For example, as shown in FIGS. 32through 35, behavior data comparer module 3416 may compare currentmeasured behavior data with expected behavior data. Current measuredbehavior data may include data obtained and/or measured from the mostrecent occurrence of administering a combination bioactive agent andartificial sensory experience to an individual. Expected behavior datamay include previous measurements from the individual and/or a separategroup of people with similar characteristics. Expected behavior data mayalso include, for example, statistical treatments of historical responsedata, such as average response measures for an individual and/or for agroup of individuals. In some instances, behavior data comparer module3416 may include a computer processor.

FIG. 40 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 40 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4002, operation 4004, and/or operation4006.

Operation 4002 illustrates modifying access to at least a portion of theartificial sensory experience to alter at least one effect of thebioactive agent. For example, as shown in FIGS. 32 through 35, accessmodifier module 3420 may modify access to a portion of the artificialsensory experience to alter at least one effect of the bioactive agent.In one instance, access modifier module 3420 may modify access to aportion of an artificial sensory experience including a photo galleryportion of a social networking website to alter at least one effect of abioactive agent such as an antidepressant. Such modified access mayfunction therapeutically to prevent access of an individual topotentially depressing, stressful, or otherwise triggering sensoryexperiences, and/or the modified access may involve presentation of asensory experience that affirmatively improves a condition (e.g., brightsunny images for a clinically depressed individual). In some instances,access modifier module 3420 may include a computer processor.

Further, operation 4004 illustrates restricting access to at least aportion of the artificial sensory experience. For example, as shown inFIGS. 32 through 35, access restrictor module 3422 may restrict accessto at least a portion of the artificial sensory experience. In oneinstance, access restrictor module 3422 may restrict access to a portionof a virtual world designed to overcome a flying phobia, where access toa portion of a simulated flying experience is prevented, for example, ajet take-off portion. In this instance, the most stressful portion ofthe flight simulation may be avoided. In some instances, accessrestrictor module 3422 may include a computer processor. Further,operation 4006 illustrates granting access to at least a portion of theartificial sensory experience. For example, as shown in FIGS. 32 through35, access granter module 3424 may grant access to at least a portion ofthe artificial sensory experience. In one instance and continuing withthe above example, access granter module 3424 may grant access to atleast a portion of a virtual world designed to overcome a flying phobia,where access to a portion of a simulated flying experience is granted,including a jet landing portion. Such a simulation presenting graduallyincreasing contact with the object of the fear may serve to provideconditioning for the individual to eventually overcome the phobia. Insome instances, access granter module 3424 may include a computerprocessor.

FIG. 41 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 41 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4102, operation 4104, and/or operation4106.

Operation 4102 illustrates modifying a visual object in an artificialsensory experience to alter at least one effect of the bioactive agent.For example, as shown in FIGS. 32 through 35, visual object modifiermodule 3426 may modify a visual object in an artificial sensoryexperience to alter at least one effect of the bioactive agent. In oneinstance and continuing with the above example, visual object modifiermodule 3426 may modify a visual object, such as adding window coversover the windows of a virtual plane in a virtual world designed toovercome a flying phobia to alter at least one effect of an anti-anxietymedication. In this example, the window covers may reduce anxietyexperienced by the individual in addition to anxiety reduction mediatedby the anti-anxiety medication. Additional examples of a visual objectmay include a virtual character (i.e., an avatar), an action performedby the avatar, and/or character attribute and/or artifact, such asfacial features, weapons, clothing, and/or tools. In some instances,visual object modifier module 3426 may include a computer processor.

Further, operation 4104 illustrates modifying a color scheme of anartificial sensory experience to alter at least one effect of thebioactive agent. For example, as shown in FIGS. 32 through 35, colorscheme modifier module 3428 may modify a color scheme of an artificialsensory experience to alter at least one effect of the bioactive agent.In one instance, color scheme modifier module 3428 may modify a colorscheme by adding brighter background lights and colors in a virtualworld designed to overcome depression to alter an effect of ananti-depression medication. Such a color scheme modification may help toovercome depression, seasonal affective disorder, and/or other disordersbecause it has been purported that color and/or light may affectnonvisual psychological processes. Discussion regarding the effects ofcolor and/or light on nonvisual psychological processes may be found inKnez, Effects of colour of light on nonvisual psychological processes, JOURNAL OF ENVIRONMENTAL PSYCHOLOGY, 21(2):201-208 (2001); M. R BassoJr., Neurobiological relationships between ambient lighting and thestartle response to acoustic stress in humans, I NT J NEuROSCI.,110(3-4):147-57 (2001), and Lam et al., The Can-SAD Study: a randomizedcontrolled trial of the effectiveness of light therapy and fluoxetine inpatients with winter seasonal affective disorder, A MERICAN JOURNAL OFPSYCHIATRY, 163(5):805-12 (2006), each incorporated by reference. Insome instances, color scheme modifier module 3428 may include a computerprocessor. Further, operation 4106 illustrates modifying at least aportion of text of an artificial sensory experience to alter at leastone effect of the bioactive agent. For example, as shown in FIGS. 32through 35, text modifier module 3430 may modify at least a portion oftext of an artificial sensory experience to alter at least one effect ofthe bioactive agent. In one instance, text modifier module 3430 maymodify a portion of instructional text in a virtual world including acomputer game to alter an effect of a bioactive agent including aprescribed herbal memory supplement. Text modification may improvememory by utilizing techniques such as underlining, highlighting,boldfacing, and/or mnemonics as discussed in Carney, R. N.,

Levin, J. R., Mnemonic instruction with a focus on transfer, J OURNAL OFEDUCATIONAL PSYCHOLOGY, 92(4):783-90, incorporated herein by reference.Another example may include instructional text providing contextual orassociative information, perhaps individualized, to aid in rememberingduring the rest of a module. Another example of text modification andmemory may include modifying the use of interactive components, e.g. viaa keyboard and/or speakers, to use multiple forms of memory input,including visual, auditory, motor, and contextual. For example, this maybe used to aid memory and/or in learning disorders such as dysgraphia,and/or memory disorders, such as in conjunction with memory-enhancingmedications, for example cholinesterase inhibitors or herbal memorysupplements. Additionally, text messages may be added and/or alteredbased on cognitive therapy but individualized for the person,affliction, and/or medication (e.g. an antidepressant and instructionsto work toward a goal within a game that will aid in refuting automaticnegative thoughts). In some instances, text modifier module 3430 mayinclude a computer processor.

FIG. 42 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 42 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4202, operation 4204, operation 4206,and/or operation 4208.

Operation 4202 illustrates altering a sound in an artificial sensoryexperience. For example, as shown in FIGS. 32 through 35, sound alterermodule 3432 may alter a sound in an artificial sensory experience. Inone instance, sound alterer module 3432 may alter a sound in a virtualworld, such as an instructor's voice tone in an instructional tutorial.This may be done as a custom-tailored feature. For example, variousvoice tones may be tested with an individual in order to find one thathas the most significant benefit for the individual, in conjunction withthe bioactive agent. In some instances, sound alterer module 3432 mayinclude a computer processor. Further, operation 4204 illustratesaltering at least a portion of music in the artificial sensoryexperience. For example, as shown in FIGS. 32 through 35, music alterermodule 3434 may alter at least a portion of music in the artificialsensory experience. In one instance, music alterer module 3434 may altera portion of music including background music in an instructionaltutorial. Music in the artificial sensory experience may include pitch,rhythm, tempo, meter, and articulation, dynamics, lyrics, timbre andtexture. In one specific instance, music alterer module 3434 may alter aportion of uptempo music to soothing classical music in an artificialsensory experience coupled with administration of an anxiolytic. Such amusic alteration may serve to provide a calming and/or relaxingenvironment where the effects of the anxiolytic may be facilitated. Inanother instance, a sound pitch may be altered to affect bone (as inhealing fractures and/or promoting bone growth) and/or sinuses(including joints). Additionally, music alterer module 3434 may includeproviding another type of sound, such as a low frequency, to aid inhealing, e.g. in conjunction with pain medication and/or ananti-inflammatory medication. In another example, the sound mayoriginate from a natural source, for instance a purr of a cat, possiblyprovided at a particular pitch, to aid in relaxation, as in conjunctionwith a tranquilizer, and/or in healing tissue in conjunction with painmedication or anti-inflammatories. Further discussion regarding lowfrequency therapeutic biomechanical stimulation may be found in vonMuggenthaler, E. K., The Felid purr: low frequency therapeuticbiomechanical stimulation, 12th International Conference on LowFrequency Noise and Vibration and its Control, Bristol, UK, Sep. 18-20,2006, Abstract located at Fauna Communications Research Institute<http://animalvoice.com/catpurrP.htm#2pAB7.%20The%20felid%20purr:%20A%20healing%20mechanism?%20Session:%20Tuesday%20Afternoon,%20Dec%2004%20Time:%203:15>,and Simos et al., U.S. patent application Ser. No. 11/262,884, eachincorporated herein by reference. In some instances, music alterermodule 3434 may include a computer processor. Further, operation 4206illustrates altering at least a portion of ambient noise in theartificial sensory experience. For example, as shown in FIGS. 32 through35, ambient noise alterer module 3436 may alter at least a portion ofambient noise in the artificial sensory experience. In one instance,ambient noise alterer module 3436 may alter the ambient noise in anartificial sensory experience including a level of white noise in theonline virtual world Second Life. Ambient noise may include white noise,background noise, such as people talking or sounds naturally occurringin nature, and/or room noise. Changing the level of white noise mayenhance the effect of an attention deficit drug such as Ritalin, or itmay enhance the sedative properties of a steep medication ortranquilizer. Further discussion of the effects of white noise may befound in Spencer, J. A. et al., White noise and sleep induction, ARCHDIS CHILD 65(1):135-7 (1990). In some instances, ambient noise alterermodule 3436 may include a computer processor. Further, operation 4208illustrates altering at least a portion of voice in the artificialsensory experience. For example, as shown in FIGS. 32 through 35, voicealterer module 3438 may alter at least a portion of voice in theartificial sensory experience. In one instance, voice alterer module3438 may alter a voice rhythm in an online tutorial. Such alteration mayenhance the effect of an attention deficit medication, for example byelimination or reduction of monotonic qualities in the voice rhythm ofthe online tutorial, for example. Some examples of a voice may include avoice recording, an artificially generated voice, and/or a human voice.In some instances, voice alterer module 3438 may include a computerprocessor.

FIG. 43 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 43 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4302, operation 4304, operation 4306,and/or operation 4308.

Operation 4302 illustrates modifying a bioactive agent dosage. Forexample, as shown in FIGS. 32 through 35, dosage modifier module 3440may modify a bioactive agent dosage. In one embodiment, dosage modifiermodule 3440 may reduce an antianxiety dose for an individualexperiencing an artificial sensory experience and exhibiting adrastically reduced heart rate. Such a dosage reduction may serve toachieve a bioactive agent effective dose, reduce one or more detectedside effects, and/or increase efficiency of the combination bioactiveagent and artificial sensory experience. One example of reducing abioactive agent dosage using a controller in an implanted device may befound in Shelton, U.S. Patent Publication No. 2008/0172044, which isincorporated herein by reference. In some instances, dosage modifiermodule 3440 may include a computer processor and/or medicalinstrumentation.

Operation 4304 illustrates modifying at least one bioactive agent in abioactive agent combination. For example, as shown in FIGS. 32 through35, bioactive agent combination modifier module 3442 may modify abioactive agent in a bioactive agent combination. A bioactive agentcombination may include two or more bioactive agents. One example of abioactive agent combination may include Caduet, which is a combinationof Norvasc and Lipitor. Another example of a combination may include amultivitamin where each individual vitamin and/or mineral is a bioactiveagent. In some instances, bioactive agent combination modifier module3442 may include a computer processor and/or medical instrumentation.

Operation 4306 illustrates modifying a bioactive agent delivery method.For example, as shown in FIGS. 32 through 35, bioactive agent deliverymodifier module 3444 may modify a bioactive agent delivery method. Inone embodiment, bioactive agent delivery modifier module 3444 may modifyan antidepressant route of administration from an intravenous deliveryto a tablet delivery. Some examples of bioactive delivery methods mayinclude mucosal administration, parenteral administration (such asintravenous, intramuscular, and/or subcutaneous administration), topicaladministration such as epicutaneous administration, inhalationaladministration, transdermal administration, and/or enteral therapy, suchas a pill taken orally, or the like. In some instances, bioactive agentdelivery modifier module 3444 may include a computer processor and/or amedical device.

Operation 4308 illustrates modifying an artificial sensory experience toenhance the efficacy of the bioactive agent. For example, as shown inFIGS. 32 through 35, efficacy enhancing modifier module 3446 may modifyan artificial sensory experience to enhance the efficacy of thebioactive agent. In one embodiment, efficacy enhancing modifier module3446 may modify a virtual world by adding uptempo music to enhance theefficacy of an antidepressant. Further discussion of music effects maybe found in Schellenberg, E. G. et al., Exposure to music and cognitiveperformance: tests of children and adults, P SYCHOLOGY OF MUSIC, Vol.35, No. 1, 5-19 (2007), incorporated herein by reference. In someinstances, efficacy enhancing modifier module 3446 may include acomputer processor.

FIG. 44 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 44 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4402, operation 4404, operation 4406,and/or operation 4408.

Operation 4402 illustrates modifying an artificial sensory experience toreduce a side effect of the bioactive agent. For example, as shown inFIGS. 32 through 35, side effect reduction modifier module 3448 maymodify an artificial sensory experience to reduce a side effect of thebioactive agent. In one instance, side effect reduction modifier module3448 may modify a virtual world by adding music and/or sounds occurringin nature for reducing a side effect including a headache due to anadministration of penicillin. Further discussion of music effects upon aside effect may be found in Siedliecki, S. L. and Good, M., Effect ofmusic on power, pain, depression and disability, J OURNAL OF ADVANCEDNURSING 54(5):553-562 (2006), and Natural distractions reduce pain—studyfinds that sights and sounds of nature aid in pain reduction—BriefArticle, M EN'S FITNESS. October 2001, each incorporated by reference.In some instances, side effect reduction modifier module 3448 mayinclude a computer processor.

Operation 4404 illustrates adding at least one of visual or audiocontent to the artificial sensory experience. For example, as shown inFIGS. 32 through 35, visual/audio content adder module 3450 may addvisual and/or audio content to the artificial sensory experience. In oneinstance, visual/audio content adder module 3450 may add audio contentincluding calming music to an artificial sensory experience including avirtual world for treating a phobia of heights. Adding may includeincreasing, creating, and/or combining content. Some examples of visualcontent may include visual objects, light amount and/or intensity, andor color schemes. Examples of audio content may include music, voices,artificial sounds, and/or white noise. In some instances, visual/audiocontent adder module 3450 may include a computer processor.

Operation 4406 illustrates deleting at least one of visual or audiocontent of the artificial sensory experience. For example, as shown inFIGS. 32 through 35, deleter module 3452 may delete at least one ofvisual or audio content of the artificial sensory experience. In oneinstance, deleter module 3452 may delete visual content including abright lighting environment in a virtual world for enhancing the effectof a medication for a migraine headache. Deleting may include reducingand/or eliminating visual and/or audio content. In some instances,deleter module 3452 may include a computer processor.

Operation 4408 illustrates adding content to the artificial sensoryexperience and deleting different content of the artificial sensoryexperience. For example, as shown in FIGS. 32 through 35, content addermodule 3454 and deleter module 3452 may add content to the artificialsensory experience and deleting different content of the artificialsensory experience. In one instance, content adder module 3454 may addclassical background music to a virtual world and deleter module 3452may delete ambient street noise, for example, using sound detectionand/or noise-cancellation technology, to enhance the effect of asedative or other similar bioactive agent. In some instances, contentadder module 3454 and deleter module 3452 may include a computerprocessor.

FIG. 45 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 45 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4502, and/or operation 4504.

Operation 4502 illustrates modifying a sensate experience to alter theat least one effect of the bioactive agent. For example, as shown inFIGS. 32 through 35, sensate experience modifier module 3456 may modifya sensate experience to alter the at least one effect of the bioactiveagent. In one instance, sensate experience modifier module 3456 maymodify a sensate experience including adding an aroma to enhance theeffect of an anxiolytic drug or other similar bioactive agent. A sensateexperience may include a thing perceived by the senses, such as anaroma, a sound, a feel, a taste, and/or a sight. In some instances,sensate experience modifier module 3456 may include a computerprocessor. Further, operation 4504 illustrates modifying at least one ofan olfactory stimulus, a haptic stimulus, a visual stimulus, an auditorystimulus, or a taste stimulus to alter the at least one effect of thebioactive agent. For example, as shown in FIGS. 32 through 35, stimulusmodifier module 3458 may modify at least one of an olfactory stimulus, ahaptic stimulus, a visual stimulus, an auditory stimulus, or a tastestimulus to alter the at least one effect of the bioactive agent. In oneinstance, stimulus modifier module 3458 may modify an olfactory stimulusby adding a floral aroma and/or gentle vibration to enhance a relaxingeffect of a sedative or other similar bioactive agent, such as anantianxiety medication. Further discussion of an olfactory stimulus maybe found in Shaw, D. et al., Anxiolytic effects of lavender oilinhalation on open-field behaviour in rats, P HYTOMEDICINE, 14(9):613-20(2007), incorporated by reference. In some instances, stimulus modifiermodule 3458 may include a computer processor.

FIG. 46 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 46 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4602, operation 4604, and/or operation4606.

Operation 4602 illustrates modifying an artificial sensory experienceimplemented on a mobile device. For example, as shown in FIGS. 32through 35, modifier module 3418 may modify an artificial sensoryexperience implemented on a mobile device. In one instance, modifiermodule 3418 may modify a virtual world implemented in a web browser on alaptop computer having wireless capability and a battery by changing abackground color theme to a brighter color theme in the virtual world.An artificial sensory experience modification, such as the color changein the above example, may enhance the effect of a bioactive agent. Forexample, modifying the color in the above example while ananti-depressant is bioavailable may create a more pleasant environmentin the artificial sensory experience. Some examples of a mobile devicemay include a laptop or notebook computer, a personal digital assistant(PDA), an ipod, a smartphone, an Enterprise digital assistant (EDA),and/or a pager. In another example, modifier module 3418 may modify acity image by providing a soothing image having fewer people in the samepart of the city and combining the modified image with an anti-anxietymedicine for alleviating a phobia, such as agoraphobia. In anotherexample, modifier module 3418 may provide a stepwise procedure, with agradually less specific procedure and/or less steps, for a compulsivepatient to follow to achieve a goal for a particular outing while takinga selective serotonin reuptake inhibitor (SSRI). In some instances,modifier module 3418 may include a computer processor. Data sent to orfrom a mobile device may be encrypted by methods known in the art topreserve the integrity of the data and the privacy of the individual'spersonal and medical information.

Operation 4604 illustrates measuring at least one effect of a painmedication and modifying a virtual world experience to alter at leastone effect of the pain medication. For example, as shown in FIGS. 32through 35, measurer module 3402 and modifier module 3418 may measure aneffect of a pain medication and modify a virtual world experience toalter at least one effect of the pain medication. In one embodiment,measurer module 3402 may measure a reduction in pain resulting from anopioid, such as hydrocodone, using a self assessment by the individual.In the same embodiment, modifier module 3418 may alter a virtual world,such as a virtual environment used for creating distractions to reducethe perception of pain, by increasing the distractions in the virtualworld. In another example, using a virtual world experience may includeusing and/or modifying a movie and/or presentation to relax theindividual and place the individual into a state of hypnosis, furtherdiscussed in Carbis et al., U.S. Patent Publication No. 2006/0247489,which is incorporated herein by reference. In some instances, measurermodule 3402 and modifier module 3418 may include a computer processorand/or medical instrumentation.

Operation 4606 illustrates measuring at least one effect of ananti-depressant medication prescribed for the individual and modifyingat least one cheerful attribute in a virtual world experience. Forexample, as shown in FIGS. 32 through 35, measurer module 3402 andmodifier module 3418 may measure an effect of an anti-depressantmedication prescribed for the individual, such as a better mood measuredby increased activity while interacting in a virtual world includingSecond Life, and modify a cheerful attribute, such as by adding abrighter color scheme for increasing the effect of the antidepressantmedication. In some instances, measurer module 3402 and modifier module3418 may include a computer processor and/or medical instrumentation.

FIG. 47 illustrates an operational flow 4700 representing exampleoperations related to measuring at least one effect of a combinedbioactive agent and artificial sensory experience on an individual,modifying at least one of the bioactive agent or the artificial sensoryexperience at least partially based on the at least one effect, andpresenting an indication of a modified combined bioactive agent andartificial sensory experience at least partially based on a modified atleast one bioactive agent or artificial sensory experience. FIG. 47illustrates an example embodiment where the example operational flow3600 of FIG. 36 may include at least one additional operation.Additional operations may include operation 4710, operation 4712,operation 4714, and/or operation 4716.

After a start operation, operation 3610, and operation 3620, theoperational flow 4700 moves to operation 4710. Operation 4710illustrates presenting an indication of a modified combined bioactiveagent and artificial sensory experience at least partially based on amodified at least one bioactive agent or artificial sensory experience.For example, as shown in FIGS. 32 through 35, indication presentermodule 3460 may present an indication of a modified combined bioactiveagent and artificial sensory experience at least partially based on amodified at least one bioactive agent or artificial sensory experience.In one embodiment, indication presenter module 3460 may present anindication of a combined prescription antianxiety medication andprescribed virtual world, in which the dosage of the antianxietymedication is a modification of a previously prescribed dosage. In someinstances, indication presenter module 3460 may include a computerprocessor.

Operation 4712 illustrates presenting to at least one output device. Forexample, as shown in FIGS. 32 through 35, output device presenter module3462 may present to at least one output device. In one example, outputdevice presenter module 3462 may present an indication of a prescriptionmedication and an artificial sensory experience to an output device 130,such as a printer 3302 at a health clinic. An output device may includeany hardware device configured for receiving computer output. Someexamples of an output device may include a printer, a monitor, a mobilephone, a speaker, and/or a visual display unit. The output device 130may be used by individual 134. In some instances, output devicepresenter module 3462 may include a computer processor. Further,operation 4714 illustrates presenting to at least one user interface.For example, as shown in FIGS. 32 through 35, user interface presentermodule 3464 may present to at least one user interface. In oneembodiment, user interface presenter module 3464 may present to atouchscreen device. A user interface may include means by which anindividual may interact with a system. Some examples of a user interfacemay include a touchscreen, a graphical user interface, a tactileinterface, and/or a live user interface. In some instances, userinterface presenter module 3464 may include a computer processor.Further, operation 4716 illustrates presenting to at least one mobiledevice. For example, as shown in FIGS. 32 through 35, mobile devicepresenter module 3466 may present to at least one mobile device. In oneembodiment, mobile device presenter module 3466 may present to a mobilephone. A mobile device may include a portable computing device and mayhave wireless connection capability. Some examples of a mobile devicemay include a laptop or notebook computer, a personal digital assistant(PDA), an ipod, a smartphone, an Enterprise digital assistant (EDA),and/or a pager. In some instances, mobile device presenter module 3466may include a computer processor.

FIG. 48 illustrates alternative embodiments of the example operationalflow 4700 of FIG. 47. FIG. 48 illustrates example embodiments whereoperation 4710 may include at least one additional operation. Additionaloperations may include operation 4802, operation 4804, and/or operation4806.

Operation 4802 illustrates presenting to a third party. For example, asshown in FIGS. 32 through 35, third party presenter module 3468 maypresent to a third party. For example, third party presenter module 3468may present to an individual's physician. A third party may include aparty that is an independent party, person, and/or entity. Some examplesof a third party may include a physician, a medical database, ahospital, a law enforcement agency, and/or a pharmacy. One example ofreporting to a third party may include creating displays and reports foraggregating data from therapy results, further discussed in Bair et al.,U.S. Pat. No. 6,067,523, which is incorporated herein by reference. Insome instances, third party presenter module 3468 may include a computerprocessor and/or a communications device. Further, operation 4804illustrates presenting to a health care provider. For example, as shownin FIGS. 32 through 35, health care provider presenter module 3470 maypresent to a health care provider. A health care provider may include apharmacy, a pharmaceutical company, a medical device company, a researchinstitution, a computer software and/or computer hardware company, awebsite, a nurse and/or a physician. In some instances, health careprovider presenter module 3470 may include a computer processor.Further, operation 4806 illustrates selectively presenting only to theindividual. For example, as shown in FIGS. 32 through 35, selectivepresenter module 3472 may selectively present only to the individual.Selective presenting may include limiting and/or blocking access ofmeasuring and/or modification results to a specific party. For example,selective presenter module 3472 may present only to individual 134 andmay keep results of a certain modification confidential. In oneembodiment, an encryption key may be employed to protect selectedinformation. In an additional example, selective presenter module 3472may report only to a law enforcement agency and/or representative, suchas a probation officer, and not to individual 134. In some instances,selective presenter module 3472 may include a computer processor.

FIG. 49 illustrates a partial view of an example computer programproduct 4900 that includes a computer program 4904 for executing acomputer process on a computing device. An embodiment of the examplecomputer program product 4900 is provided using a signal-bearing medium4902, and may include one or more instructions for measuring at leastone effect of a combined bioactive agent and artificial sensoryexperience on an individual and one or more instructions for modifyingat least one of the bioactive agent or the artificial sensory experienceat least partially based on the at least one effect. The one or moreinstructions may be, for example, computer executable and/orlogic-implemented instructions. In one implementation, thesignal-bearing medium 4902 may include a computer-readable medium 4906.In one implementation, the signal bearing medium 4902 may include arecordable medium 4908. In one implementation, the signal bearing medium4902 may include a communications medium 4910.

FIG. 50 illustrates an example system 5000 in which embodiments may beimplemented. The system 5000 includes a computing system environment.The system 5000 also illustrates the user 118 using a device 5004, whichis optionally shown as being in communication with a computing device5002 by way of an optional coupling 5006. The optional coupling 5006 mayrepresent a local, wide-area, or peer-to-peer network, or may representa bus that is internal to a computing device (e.g., in exampleembodiments in which the computing device 5002 is contained in whole orin part within the device 5004). A storage medium 5008 may be anycomputer storage media.

The computing device 5002 includes computer-executable instructions 5010that when executed on the computing device 5002 cause the computingdevice 5002 to measure at least one effect of a combined bioactive agentand artificial sensory experience on an individual and modify at leastone of the bioactive agent or the artificial sensory experience at leastpartially based on the at least one effect. As referenced above and asshown in FIG. 50, in some examples, the computing device 5002 mayoptionally be contained in whole or in part within the device 5004.

In FIG. 50, then, the system 5000 includes at least one computing device(e.g., 5002 and/or 5004). The computer-executable instructions 5010 maybe executed on one or more of the at least one computing device. Forexample, the computing device 5002 may implement the computer-executableinstructions 5010 and output a result to (and/or receive data from) thecomputing device 5004. Since the computing device 5002 may be wholly orpartially contained within the computing device 5004, the device 5004also may be said to execute some or all of the computer-executableinstructions 5010, in order to be caused to perform or implement, forexample, various ones of the techniques described herein, or othertechniques.

The device 5004 may include, for example, a portable computing device,workstation, or desktop computing device. In another example embodiment,the computing device 5002 is operable to communicate with the device5004 associated with the user 118 to receive information about the inputfrom the user 118 for performing data access and data processing andpresenting an output of the user-health test function at least partlybased on the user data.

Although a user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that a user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents). In addition, a user 118, asset forth herein, although shown as a single entity may in fact becomposed of two or more entities. Those skilled in the art willappreciate that, in general, the same may be said of “sender” and/orother entity-oriented terms as such terms are used herein.

Following are a series of flowcharts depicting implementations. For easeof understanding, the flowcharts are organized such that the initialflowcharts present implementations via an example implementation andthereafter the following flowcharts present alternate implementationsand/or expansions of the initial flowchart(s) as either sub-componentoperations or additional component operations building on one or moreearlier-presented flowcharts. Those having skill in the art willappreciate that the style of presentation utilized herein (e.g.,beginning with a presentation of a flowchart(s) presenting an exampleimplementation and thereafter providing additions to and/or furtherdetails in subsequent flowcharts) generally allows for a rapid and easyunderstanding of the various process implementations. In addition, thoseskilled in the art will further appreciate that the style ofpresentation used herein also lends itself well to modular and/orobject-oriented program design paradigms.

Those skilled in the art will appreciate that the foregoing specificexemplary processes and/or devices and/or technologies arerepresentative of more general processes and/or devices and/ortechnologies taught elsewhere herein, such as in the claims filedherewith and/or elsewhere in the present application.

Those having skill in the art will recognize that the state of the arthas progressed to the point where there is little distinction leftbetween hardware, software, and/or firmware implementations of aspectsof systems; the use of hardware, software, and/or firmware is generally(but not always, in that in certain contexts the choice between hardwareand software can become significant) a design choice representing costvs. efficiency tradeoffs. Those having skill in the art will appreciatethat there are various vehicles by which processes and/or systems and/orother technologies described herein can be effected (e.g., hardware,software, and/or firmware), and that the preferred vehicle will varywith the context in which the processes and/or systems and/or othertechnologies are deployed. For example, if an implementer determinesthat speed and accuracy are paramount, the implementer may opt for amainly hardware and/or firmware vehicle; alternatively, if flexibilityis paramount, the implementer may opt for a mainly softwareimplementation; or, yet again alternatively, the implementer may opt forsome combination of hardware, software, and/or firmware. Hence, thereare several possible vehicles by which the processes and/or devicesand/or other technologies described herein may be effected, none ofwhich is inherently superior to the other in that any vehicle to beutilized is a choice dependent upon the context in which the vehiclewill be deployed and the specific concerns (e.g., speed, flexibility, orpredictability) of the implementer, any of which may vary. Those skilledin the art will recognize that optical aspects of implementations willtypically employ optically-oriented hardware, software, and or firmware.

In some implementations described herein, logic and similarimplementations may include software or other control structuressuitable to operation. Electronic circuitry, for example, may manifestone or more paths of electrical current constructed and arranged toimplement various logic functions as described herein. In someimplementations, one or more media are configured to bear adevice-detectable implementation if such media hold or transmit aspecial-purpose device instruction set operable to perform as describedherein. In some variants, for example, this may manifest as an update orother modification of existing software or firmware, or of gate arraysor other programmable hardware, such as by performing a reception of ora transmission of one or more instructions in relation to one or moreoperations described herein. Alternatively or additionally, in somevariants, an implementation may include special-purpose hardware,software, firmware components, and/or general-purpose componentsexecuting or otherwise invoking special-purpose components.Specifications or other implementations may be transmitted by one ormore instances of tangible transmission media as described herein,optionally by packet transmission or otherwise by passing throughdistributed media at various times.

Alternatively or additionally, implementations may include executing aspecial-purpose instruction sequence or otherwise invoking circuitry forenabling, triggering, coordinating, requesting, or otherwise causing oneor more occurrences of any functional operations described above. Insome variants, operational or other logical descriptions herein may beexpressed directly as source code and compiled or otherwise invoked asan executable instruction sequence. In some contexts, for example, C++or other code sequences can be compiled directly or otherwiseimplemented in high-level descriptor languages (e.g., alogic-synthesizable language, a hardware description language, ahardware design simulation, and/or other such similar mode(s) ofexpression). Alternatively or additionally, some or all of the logicalexpression may be manifested as a Verilog-type hardware description orother circuitry model before physical implementation in hardware,especially for basic operations or timing-critical applications. Thoseskilled in the art will recognize how to obtain, configure, and optimizesuitable transmission or computational elements, material supplies,actuators, or other common structures in light of these teachings.

The foregoing detailed description has set forth various embodiments ofthe devices and/or processes via the use of block diagrams, flowcharts,and/or examples. Insofar as such block diagrams, flowcharts, and/orexamples contain one or more functions and/or operations, it will beunderstood by those within the art that each function and/or operationwithin such block diagrams, flowcharts, or examples can be implemented,individually and/or collectively, by a wide range of hardware, software,firmware, or virtually any combination thereof. In one embodiment,several portions of the subject matter described herein may beimplemented via Application Specific Integrated Circuits (ASICs), FieldProgrammable Gate Arrays (FPGAs), digital signal processors (DSPs), orother integrated formats. However, those skilled in the art willrecognize that some aspects of the embodiments disclosed herein, inwhole or in part, can be equivalently implemented in integratedcircuits, as one or more computer programs running on one or morecomputers (e.g., as one or more programs running on one or more computersystems), as one or more programs running on one or more processors(e.g., as one or more programs running on one or more microprocessors),as firmware, or as virtually any combination thereof, and that designingthe circuitry and/or writing the code for the software and or firmwarewould be well within the skill of one of skill in the art in tight ofthis disclosure. In addition, those skilled in the art will appreciatethat the mechanisms of the subject matter described herein are capableof being distributed as a program product in a variety of forms, andthat an illustrative embodiment of the subject matter described hereinapplies regardless of the particular type of signal bearing medium usedto actually carry out the distribution. Examples of a signal bearingmedium include, but are not limited to, the following: a recordable typemedium such as a floppy disk, a hard disk drive, a Compact Disc (CD), aDigital Video Disk (DVD), a digital tape, a computer memory, etc.; and atransmission type medium such as a digital and/or an analogcommunication medium (e.g., a fiber optic cable, a waveguide, a wiredcommunications link, a wireless communication link (e.g., transmitter,receiver, transmission logic, reception logic, etc.), etc.).

In a general sense, those skilled in the art will recognize that thevarious embodiments described herein can be implemented, individuallyand/or collectively, by various types of electro-mechanical systemshaving a wide range of electrical components such as hardware, software,firmware, and/or virtually any combination thereof; and a wide range ofcomponents that may impart mechanical force or motion such as rigidbodies, spring or torsional bodies, hydraulics, electro-magneticallyactuated devices, and/or virtually any combination thereof.Consequently, as used herein “electro-mechanical system” includes, butis not limited to, electrical circuitry operably coupled with atransducer (e.g., an actuator, a motor, a piezoelectric crystal, a MicroElectro Mechanical System (MEMS), etc.), electrical circuitry having atleast one discrete electrical circuit, electrical circuitry having atleast one integrated circuit, electrical circuitry having at least oneapplication specific integrated circuit, electrical circuitry forming ageneral purpose computing device configured by a computer program (e.g.,a general purpose computer configured by a computer program which atleast partially carries out processes and/or devices described herein,or a microprocessor configured by a computer program which at leastpartially carries out processes and/or devices described herein),electrical circuitry forming a memory device (e.g., forms of memory(e.g., random access, flash, read only, etc.)), electrical circuitryforming a communications device (e.g., a modem, communications switch,optical-electrical equipment, etc.), and/or any non-electrical analogthereto, such as optical or other analogs. Those skilled in the art willalso appreciate that examples of electro-mechanical systems include butare not limited to a variety of consumer electronics systems, medicaldevices, as well as other systems such as motorized transport systems,factory automation systems, security systems, and/orcommunication/computing systems. Those skilled in the art wilt recognizethat electro-mechanical as used herein is not necessarily limited to asystem that has both electrical and mechanical actuation except ascontext may dictate otherwise.

In a general sense, those skilled in the art will recognize that thevarious aspects described herein which can be implemented, individuallyand/or collectively, by a wide range of hardware, software, firmware,and/or any combination thereof can be viewed as being composed ofvarious types of “electrical circuitry.” Consequently, as used herein“electrical circuitry” includes, but is not limited to, electricalcircuitry having at least one discrete electrical circuit, electricalcircuitry having at least one integrated circuit, electrical circuitryhaving at least one application specific integrated circuit, electricalcircuitry forming a general purpose computing device configured by acomputer program (e.g., a general purpose computer configured by acomputer program which at least partially carries out processes and/ordevices described herein, or a microprocessor configured by a computerprogram which at least partially carries out processes and/or devicesdescribed herein), electrical circuitry forming a memory device (e.g.,forms of memory (e.g., random access, flash, read only, etc.)), and/orelectrical circuitry forming a communications device (e.g., a modem,communications switch, optical-electrical equipment, etc.). Those havingskill in the art will recognize that the subject matter described hereinmay be implemented in an analog or digital fashion or some combinationthereof.

Those skilled in the art will recognize that at least a portion of thedevices and/or processes described herein can be integrated into a dataprocessing system. Those having skill in the art will recognize that adata processing system generally includes one or more of a system unithousing, a video display device, memory such as volatile or non-volatilememory, processors such as microprocessors or digital signal processors,computational entities such as operating systems, drivers, graphicaluser interfaces, and applications programs, one or more interactiondevices (e.g., a touch pad, a touch screen, an antenna, etc.), and/orcontrol systems including feedback loops and control motors (e.g.,feedback for sensing position and/or velocity; control motors for movingand/or adjusting components and/or quantities). A data processing systemmay be implemented utilizing suitable commercially available components,such as those typically found in data computing/communication and/ornetwork computing/communication systems.

Those skilled in the art will recognize that it is common within the artto implement devices and/or processes and/or systems, and thereafter useengineering and/or other practices to integrate such implemented devicesand/or processes and/or systems into more comprehensive devices and/orprocesses and/or systems. That is, at least a portion of the devicesand/or processes and/or systems described herein can be integrated intoother devices and/or processes and/or systems via a reasonable amount ofexperimentation. Those having skill in the art will recognize thatexamples of such other devices and/or processes and/or systems mightinclude—as appropriate to context and application—all or part of devicesand/or processes and/or systems of (a) an air conveyance (e.g., anairplane, rocket, helicopter, etc.), (b) a ground conveyance (e.g., acar, truck, locomotive, tank, armored personnel carrier, etc.), (c) abuilding (e.g., a home, warehouse, office, etc.), (d) an appliance(e.g., a refrigerator, a washing machine, a dryer, etc.), (e) acommunications system (e.g., a networked system, a telephone system, aVoice over IP system, etc.), (f) a business entity (e.g., an InternetService Provider (ISP) entity such as Comcast Cable, Qwest, SouthwesternBell, etc.), or (g) a wired/wireless services entity (e.g., Sprint,Cingular, Nextel, etc.), etc.

In certain cases, use of a system or method may occur in a territoryeven if components are located outside the territory. For example, in adistributed computing context, use of a distributed computing system mayoccur in a territory even though parts of the system may be locatedoutside of the territory (e.g., relay, server, processor, signal-bearingmedium, transmitting computer, receiving computer, etc. located outsidethe territory).

A sale of a system or method may likewise occur in a territory even ifcomponents of the system or method are located and/or used outside theterritory.

Further, implementation of at least part of a system for performing amethod in one territory does not preclude use of the system in anotherterritory.

All of the above U.S. patents, U.S. patent application publications,U.S. patent applications, foreign patents, foreign patent applicationsand non-patent publications referred to in this specification and/orlisted in any Application Data Sheet, are incorporated herein byreference, to the extent not inconsistent herewith.

One skilled in the art will recognize that the herein describedcomponents (e.g., operations), devices, objects, and the discussionaccompanying them are used as examples for the sake of conceptualclarity and that various configuration modifications are contemplated.Consequently, as used herein, the specific exemplars set forth and theaccompanying discussion are intended to be representative of their moregeneral classes. In general, use of any specific exemplar is intended tobe representative of its class, and the non-inclusion of specificcomponents (e.g., operations), devices, and objects should not be takenlimiting.

Although user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents) unless context dictatesotherwise. Those skilled in the art will appreciate that, in general,the same may be said of “sender” and/or other entity-oriented terms assuch terms are used herein unless context dictates otherwise.

With respect to the use of substantially any plural and/or singularterms herein, those having skill in the art can translate from theplural to the singular and/or from the singular to the plural as isappropriate to the context and/or application. The varioussingular/plural permutations are not expressly set forth herein for sakeof clarity.

The herein described subject matter sometimes illustrates differentcomponents contained within, or connected with, different othercomponents. It is to be understood that such depicted architectures aremerely exemplary, and that in fact many other architectures may beimplemented which achieve the same functionality. In a conceptual sense,any arrangement of components to achieve the same functionality iseffectively “associated” such that the desired functionality isachieved. Hence, any two components herein combined to achieve aparticular functionality can be seen as “associated with” each othersuch that the desired functionality is achieved, irrespective ofarchitectures or intermedial components. Likewise, any two components soassociated can also be viewed as being “operably connected”, or“operably coupled,” to each other to achieve the desired functionality,and any two components capable of being so associated can also be viewedas being “operably couplable,” to each other to achieve the desiredfunctionality. Specific examples of operably couplable include but arenot limited to physically mateable and/or physically interactingcomponents, and/or wirelessly interactable, and/or wirelesslyinteracting components, and/or logically interacting, and/or logicallyinteractable components.

In some instances, one or more components may be referred to herein as“configured to,” “configurable to,” “operable/operative to,”“adapted/adaptable,” “able to,” “conformable/conformed to,” etc. Thoseskilled in the art will recognize that “configured to” can generallyencompass active-state components and/or inactive-state componentsand/or standby-state components, unless context requires otherwise.

White particular aspects of the present subject matter described hereinhave been shown and described, it will be apparent to those skilled inthe art that, based upon the teachings herein, changes and modificationsmay be made without departing from the subject matter described hereinand its broader aspects and, therefore, the appended claims are toencompass within their scope all such changes and modifications as arewithin the true spirit and scope of the subject matter described herein.It will be understood by those within the art that, in general, termsused herein, and especially in the appended claims (e.g., bodies of theappended claims) are generally intended as “open” terms (e.g., the term“including” should be interpreted as “including but not limited to,” theterm “having” should be interpreted as “having at least,” the term“includes” should be interpreted as “includes but is not limited to,”etc.). It will be further understood by those within the art that if aspecific number of an introduced claim recitation is intended, such anintent will be explicitly recited in the claim, and in the absence ofsuch recitation no such intent is present. For example, as an aid tounderstanding, the following appended claims may contain usage of theintroductory phrases “at least one” and “one or more” to introduce claimrecitations. However, the use of such phrases should not be construed toimply that the introduction of a claim recitation by the indefinitearticles “a” or “an” limits any particular claim containing suchintroduced claim recitation to claims containing only one suchrecitation, even when the same claim includes the introductory phrases“one or more” or “at least one” and indefinite articles such as “a” or“an” (e.g., “a” and/or “an” should typically be interpreted to mean “atleast one” or “one or more”); the same holds true for the use ofdefinite articles used to introduce claim recitations. In addition, evenif a specific number of an introduced claim recitation is explicitlyrecited, those skilled in the art will recognize that such recitationshould typically be interpreted to mean at least the recited number(e.g., the bare recitation of “two recitations,” without othermodifiers, typically means at least two recitations, or two or morerecitations). Furthermore, in those instances where a conventionanalogous to “at least one of A, B, and C, etc.” is used, in generalsuch a construction is intended in the sense one having skill in the artwould understand the convention (e.g., “a system having at least one ofA, B, and C” would include but not be limited to systems that have Aalone, B alone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). In those instances where aconvention analogous to “at least one of A, B, or C, etc.” is used, ingeneral such a construction is intended in the sense one having skill inthe art would understand the convention (e.g., “a system having at leastone of A, B, or C” would include but not be limited to systems that haveA alone, B alone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). It will be furtherunderstood by those within the art that typically a disjunctive wordand/or phrase presenting two or more alternative terms, whether in thedescription, claims, or drawings, should be understood to contemplatethe possibilities of including one of the terms, either of the terms, orboth terms unless context dictates otherwise. For example, the phrase “Aor B” will be typically understood to include the possibilities of “A”or “B” or “A and B.”

With respect to the appended claims, those skilled in the art willappreciate that recited operations therein may generally be performed inany order. Also, although various operational flows are presented in asequence(s), it should be understood that the various operations may beperformed in other orders than those which are illustrated, or may beperformed concurrently. Examples of such alternate orderings may includeoverlapping, interleaved, interrupted, reordered, incremental,preparatory, supplemental, simultaneous, reverse, or other variantorderings, unless context dictates otherwise. Furthermore, terms like“responsive to,” “related to,” or other past-tense adjectives aregenerally not intended to exclude such variants, unless context dictatesotherwise.

While various aspects and embodiments have been disclosed herein, otheraspects and embodiments will be apparent to those skilled in the art.The various aspects and embodiments disclosed herein are for purposes ofillustration and are not intended to be limiting, with the true scopeand spirit being indicated by the following claims.

What is claimed is:
 1. A system comprising: at least one administrationunit including at least: one or more dosages of at least oneprescription medication; and at least one mobile electronic computingdevice, the at least one mobile electronic computing device including atleast: at least one user interface; at least one wireless communicationunit operable to communicate via the at least one wireless communicationunit; at least one non-transitory storage medium including one or moreexecutable instructions; and at least one processor operativelyconnected to the at least one non-transitory storage medium, the atleast one processor configured to execute the one or more executableinstructions to perform operations including at least: measuring atleast one health parameter before, during or after stimulation includingat least visual content and administration of a dosage amount of the atleast one prescription medication; determining a new dosage amount ofthe at least one prescription medication for administration from the atleast one administration unit at least partly based on the at least onemeasured health parameter; and outputting one or more instructions atone or more specified times to administer the new dosage amount of theat least one prescription medication from the at least oneadministration unit.
 2. A system comprising: at least one monitoringunit configured to monitor at least one health parameter; and at leastone smartphone device wirelessly linked with the at least one monitoringunit, the at least one smartphone device including at least: a display;a wireless communication unit; at least one storage medium including oneor more executable instructions; and at least one processor operativelyconnected to the at least one storage medium, the at least one processorconfigured to execute the one or more executable instructions to performoperations including at least: measuring the at least one healthparameter of an individual before, during, or after at least one ofimplementation of at least one digital therapy application oradministration of at least one medication; determining a new dosageamount of the at least one medication for administration to theindividual at least partly based on the at least one health parametermeasured before, during, or after at least one of implementation of theat least one digital therapy application or administration of the atleast one medication; and controlling at least one output to present atone or more specified times at least one indication to administer thenew dosage amount of the at least one medication.
 3. The system of claim2, wherein the at least one monitoring unit comprises: a drug sensingunit, a physiological activity monitor, a brain activity measurementunit, a behavior monitor, an instrumentation monitor, a compliancereporting unit, a voice response module, a hearing test module, animager, a wearable device, or a scale.
 4. A computer process forcontrolling a smartphone device that includes at least a user interface,a wireless communication unit, at least one storage medium including oneor more computer-executable instructions, and at least one computingdevice operatively connected to the at least one storage medium, thecomputer process including operations comprising: measuring at least onehealth parameter of an individual in association with at least one ofimplementation of at least one digital therapy application oradministration of at least one medication; determining at least one of anew dosage of the at least one medication or a modification in the atleast one digital therapy application at least partly based on the atleast one health parameter measured in association with at least one ofimplementation of the at least one digital therapy application oradministration of the at least one medication; and outputting at one ormore times at least one indication to at least one of administer the newdosage of the at least one medication or implement the at least onemodified digital therapy application.
 5. The computer process of claim4, wherein the measuring at least one health parameter of an individualin association with at least one of implementation of at least onedigital therapy application or administration of at least one medicationcomprises: measuring at least one health parameter of an individualusing at least one of the following monitoring units: a drug sensingunit, a physiological activity monitor, a brain activity measurementunit, a behavior monitor, an instrumentation monitor, a compliancereporting unit, a voice response module, a hearing test module, animager, or a scale.
 6. The computer process of claim 4, wherein themeasuring at least one health parameter of an individual in associationwith at least one of implementation of at least one digital therapyapplication or administration of at least one medication comprises:measuring at least one parameter associated with at least one of thefollowing in association with at least one of implementation of at leastone digital therapy application or administration of at least onemedication: physiological activity, compliance, voice response, hearing,pain, sweating, dizziness, lightheadedness, respiration, headache,fatigue, nausea, fever, heart rhythm, motor weakness, heart rate,physical attribute, disease, illness, bodily impairment, diagnosis,disorder, mental symptom, anxiety, appearance, behavior, depression,fear, inattention, mood, phobia, psychological test result, brainactivity, cardiac activity, neural signals, mental impairment, psychoticdisorder, eating disorder, developmental disorder, communicationdisorder, social disorder, personality disorder, mental diagnosis,panic, bipolar, schizophrenia, obsessive disorder, or PTSD.
 7. Thecomputer process of claim 4, wherein the measuring at least one healthparameter of an individual in association with at least one ofimplementation of at least one digital therapy application oradministration of at least one medication comprises: measuring at leastone health parameter of an individual using at least one of thefollowing methodologies: self-assessment or score.
 8. The computerprocess of claim 4, wherein the measuring at least one health parameterof an individual in association with at least one of implementation ofat least one digital therapy application or administration of at leastone medication comprises: measuring at least one health parameter of anindividual before, during, or after at least one of implementation of atleast one digital therapy application or administration of at least onemedication.
 9. The computer process of claim 4, wherein the measuring atleast one health parameter of an individual in association with at leastone of implementation of at least one digital therapy application oradministration of at least one medication comprises: measuring at leastone health parameter of an individual following implementation of atleast one digital therapy application and during bioavailability of atleast one medication.
 10. The computer process of claim 4, wherein themeasuring at least one health parameter of an individual in associationwith at least one of implementation of at least one digital therapyapplication or administration of at least one medication comprises:measuring at least one health parameter of an individual in associationwith implementation of at least one of the following types of digitaltherapy applications: cognitive assessment tool, computer-implementedexperience, computer game, social networking site, virtual experience,simulated reality, virtual tour, interactive virtual world, oreducational experience.
 11. The computer process of claim 4, wherein themeasuring at least one health parameter of an individual in associationwith at least one of implementation of at least one digital therapyapplication or administration of at least one medication comprises:measuring at least one health parameter of an individual in associationwith administration of at least one of the following types ofmedications: bioactive agent, prescription medication, dietarysupplement, enteral, parenteral, transdermal, inhalation, analgesic,anti-depressant, anti-anxiety, anti-manic, mood stabilizer, stimulant,sleeping agent, attention deficit, anti-addiction, schizophrenia, oranti-psychotic.
 12. The computer process of claim 4, wherein thedetermining at least one of a new dosage of the at least one medicationor a modification in the at least one digital therapy application atleast partly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication comprises: determining at least one of the following types ofmodifications in the at least one digital therapy application at leastpartly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication: access, object, sound, content, or music.
 13. The computerprocess of claim 4, wherein the determining at least one of a new dosageof the at least one medication or a modification in the at least onedigital therapy application at least partly based on the at least onehealth parameter measured in association with at least one ofimplementation of the at least one digital therapy application oradministration of the at least one medication comprises: determining anew agent, amount, or delivery method of the at least one medication atleast partly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication.
 14. The computer process of claim 4, wherein the determiningat least one of a new dosage of the at least one medication or amodification in the at least one digital therapy application at leastpartly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication comprises: determining a new dosage of the at least onemedication and a modification in the at least one digital therapyapplication at least partly based on the at least one health parametermeasured in association with at least one of implementation of the atleast one digital therapy application or administration of the at leastone medication.
 15. The computer process of claim 4, wherein thedetermining at least one of a new dosage of the at least one medicationor a modification in the at least one digital therapy application atleast partly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication comprises: determining a new dosage of the at least onemedication to achieve an effective dose based on the at least one healthparameter measured in association with at least one of implementation ofthe at least one digital therapy application or administration of the atleast one medication.
 16. The computer process of claim 4, wherein thedetermining at least one of a new dosage of the at least one medicationor a modification in the at least one digital therapy application atleast partly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication comprises: determining a modification in the at least onedigital therapy application to reduce a side effect or increase efficacyof the at least one medication at least partly based on the at least onehealth parameter measured in association with at least one ofimplementation of the at least one digital therapy application oradministration of the at least one medication.
 17. The computer processof claim 4, wherein the outputting at one or more times at least oneindication to at least one of administer the new dosage of the at leastone medication or implement the at least one modified digital therapyapplication comprises: outputting at one or more times based onmedication bioavailability at least one indication to implement the atleast one modified digital therapy application.
 18. The computer processof claim 4, wherein the outputting at one or more times at least oneindication to at least one of administer the new dosage of the at leastone medication or implement the at least one modified digital therapyapplication comprises: outputting at one or more relative staggeredtimes at least one indication to administer the new dosage of the atleast one medication and to implement the at least one modified digitaltherapy application.
 19. The computer process of claim 4, wherein theoutputting at one or more times at least one indication to at least oneof administer the new dosage of the at least one medication or implementthe at least one modified digital therapy application comprises:controlling at least one administration unit to administer the newdosage of the at least one medication.
 20. The computer process of claim4, wherein the outputting at one or more times at least one indicationto at least one of administer the new dosage of the at least onemedication or implement the at least one modified digital therapyapplication comprises: presenting at one or more times at least oneindication to at least one of administer the new dosage of the at leastone medication or implement the at least one modified digital therapyapplication.
 21. The computer process of claim 4, wherein the outputtingat one or more times at least one indication to at least one ofadminister the new dosage of the at least one medication or implementthe at least one modified digital therapy application comprises:outputting via the wireless communication unit at least one indicationto at least one of administer the new dosage of the at least onemedication or implement the at least one modified digital therapyapplication.
 22. The computer process of claim 4, wherein the measuringat least one health parameter of an individual in association with atleast one of implementation of at least one digital therapy applicationor administration of at least one medication comprises: measuring painof an individual in association with administration of at least one painmedication, wherein the determining at least one of a new dosage of theat least one medication or a modification in the at least one digitaltherapy application at least partly based on the at least one healthparameter measured in association with at least one of implementation ofthe at least one digital therapy application or administration of the atleast one medication includes, but is not limited to, determining amodification in the at least one digital therapy application to increasedistraction to the individual, and wherein the outputting at one or moretimes at least one indication to at least one of administer the newdosage of the at least one medication or implement the at least onemodified digital therapy application includes, but is not limited to,outputting at least one indication to implement the at least onemodified digital therapy application to increase distraction to theindividual at one or more staggered times relative to administration ofthe pain medication.
 23. The computer process of claim 4, wherein themeasuring at least one health parameter of an individual in associationwith at least one of implementation of at least one digital therapyapplication or administration of at least one medication comprises:measuring depression of an individual in association with administrationof at least one anti-depressant medication, wherein the determining atleast one of a new dosage of the at least one medication or amodification in the at least one digital therapy application at leastpartly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication includes, but is not limited to, determining a modificationin the at least one digital therapy application to increase mood of theindividual, and wherein the outputting at one or more times at least oneindication to at least one of administer the new dosage of the at leastone medication or implement the at least one modified digital therapyapplication includes, but is not limited to, outputting at least oneindication to implement the at least one modified digital therapyapplication to increase mood of the individual in association withadministration of the anti-depressant medication.
 24. The computerprocess of claim 4, wherein the measuring at least one health parameterof an individual in association with at least one of implementation ofat least one digital therapy application or administration of at leastone medication comprises: measuring heart rate of an individual inassociation with administration of at least one anti-anxiety medication,wherein the determining at least one of a new dosage of the at least onemedication or a modification in the at least one digital therapyapplication at least partly based on the at least one health parametermeasured in association with at least one of implementation of the atleast one digital therapy application or administration of the at leastone medication includes, but is not limited to, determining amodification in the at least one digital therapy application to increaseexposure of the individual to at least one specified anxiety-inducingsituation, and wherein the outputting at one or more times at least oneindication to at least one of administer the new dosage of the at leastone medication or implement the at least one modified digital therapyapplication includes, but is not limited to, outputting at least oneindication to implement the at least one modified digital therapyapplication to increase exposure of the individual to the at least onespecified anxiety-inducing situation in association with administrationof the anti-anxiety medication.
 25. The computer process of claim 4,wherein the measuring at least one health parameter of an individual inassociation with at least one of implementation of at least one digitaltherapy application or administration of at least one medicationcomprises: measuring heart rate of an individual in association withadministration of at least one anti-anxiety medication andimplementation of at least one digital therapy application, wherein thedetermining at least one of a new dosage of the at least one medicationor a modification in the at least one digital therapy application atleast partly based on the at least one health parameter measured inassociation with at least one of implementation of the at least onedigital therapy application or administration of the at least onemedication includes, but is not limited to, determining a reduced dosageamount of the anti-anxiety medication based on a detected reduction inmeasured heart rate of the individual, and wherein the outputting at oneor more times at least one indication to at least one of administer thenew dosage of the at least one medication or implement the at least onemodified digital therapy application includes, but is not limited to,outputting at least one indication to administer the reduced dosageamount of the anti-anxiety medication in response to the detectedreduction in measured heart rate.
 26. The computer process of claim 4,wherein the measuring at least one health parameter of an individual inassociation with at least one of implementation of at least one digitaltherapy application or administration of at least one medicationcomprises: measuring at least one health parameter of an individual inassociation with administration of at least one attention deficitmedication, wherein the determining at least one of a new dosage of theat least one medication or a modification in the at least one digitaltherapy application at least partly based on the at least one healthparameter measured in association with at least one of implementation ofthe at least one digital therapy application or administration of the atleast one medication includes, but is not limited to, determining avoice or rhythm modification in the at least one digital therapyapplication based on the at least one measured health parameter, andwherein the outputting at one or more times at least one indication toat least one of administer the new dosage of the at least one medicationor implement the at least one modified digital therapy applicationincludes, but is not limited to, outputting at least one indication toimplement the at least one modified digital therapy application havingthe voice or rhythm modification in association with administration ofthe attention-deficit medication.
 27. A computer process for controllinga smartphone device that includes at least a display, a wirelesscommunication unit, memory, and a processor component, the computerprocess including operations comprising: obtaining at least onemeasurement of at least one health parameter of an individual inassociation with administration of at least one medication; determininga new dosage of the at least one medication at least partly based on theat least one measurement of the at least one health parameter obtainedin association with administration of the at least one medication; andmonitoring the at least one health parameter of the individual at leastpartly in response to administration of the new dosage of the at leastone medication.
 28. The computer process of claim 27, wherein theobtaining at least one measurement of at least one health parameter ofan individual in association with administration of at least onemedication comprises: obtaining at least one measurement of pain of anindividual in association with administration of at least one painmedication, wherein the determining a new dosage of the at least onemedication at least partly based on the at least one measurement of theat least one health parameter obtained in association withadministration of the at least one medication includes, but is notlimited to, determining a new dosage of the at least one pain medicationat least partly based on the at least one measurement of pain obtainedin association with administration of the at least one pain medication,wherein the computer process further includes, but is not limited to,implementing at least one stimulus at one or more staggered timesrelative to administration of the new dosage of the at least one painmedication to distract the individual from pain.
 29. The computerprocess of claim 27, wherein the obtaining at least one measurement ofat least one health parameter of an individual in association withadministration of at least one medication comprises: obtaining at leastone measurement of depression of an individual in association withadministration of at least one anti-depressant medication, wherein thedetermining a new dosage of the at least one medication at least partlybased on the at least one measurement of the at least one healthparameter obtained in association with administration of the at leastone medication includes, but is not limited to, determining a new dosageof the at least one anti-depressant medication at least partly based onthe at least one measurement of depression obtained in association withadministration of the at least one anti-depressant medication, whereinthe computer process further includes, but is not limited to,implementing at least one stimulus at one or more staggered timesrelative to administration of the new dosage of the at least oneanti-depressant medication to increase mood of the individual.
 30. Thecomputer process of claim 27, wherein the obtaining at least onemeasurement of at least one health parameter of an individual inassociation with administration of at least one medication comprises:obtaining at least one measurement of heart rate of an individual inassociation with administration of at least one anti-anxiety medication,wherein the determining a new dosage of the at least one medication atleast partly based on the at least one measurement of the at least onehealth parameter obtained in association with administration of the atleast one medication includes, but is not limited to, determining a newdosage of the at least one anti-anxiety medication at least partly basedon the at least one measurement of heart rate obtained in associationwith administration of the at least one anti-anxiety medication, whereinthe computer process further includes, but is not limited to,implementing at least one stimulus at one or more staggered timesrelative to administration of the new dosage of the at least oneanti-anxiety medication to expose the individual to a simulatedanxiety-inducing experience.
 31. The computer process of claim 27,wherein the obtaining at least one measurement of at least one healthparameter of an individual in association with administration of atleast one medication comprises: obtaining at least one measurement offocus of an individual in association with administration of at leastone attention-deficit medication, wherein the determining a new dosageof the at least one medication at least partly based on the at least onemeasurement of the at least one health parameter obtained in associationwith administration of the at least one medication includes, but is notlimited to, determining a new dosage of the at least oneattention-deficit medication at least partly based on the at least onemeasurement of focus obtained in association with administration of theat least one attention-deficit medication, wherein the computer processfurther includes, but is not limited to, implementing at least one soundwith at least one attribute selected based on the at least onemeasurement of focus, at one or more staggered times relative toadministration of the new dosage of the at least one attention-deficitmedication.
 32. A method comprising: measuring, by a processor, at leastone health parameter of an individual before, during or afterimplementation of at least one computer-implemented experience andadministration of a dosage of at least one prescription medication;determining, by the processor, a new dosage amount of the at least oneprescription medication for administration from at least oneadministration unit at least partly based on the at least one measuredhealth parameter; and controlling, by the processor, the at least oneadministration unit to administer the new dosage amount of the at leastone prescription medication at one or more specified times.